WO2012151468A1 - Complement factor b analogs and their uses - Google Patents
Complement factor b analogs and their uses Download PDFInfo
- Publication number
- WO2012151468A1 WO2012151468A1 PCT/US2012/036459 US2012036459W WO2012151468A1 WO 2012151468 A1 WO2012151468 A1 WO 2012151468A1 US 2012036459 W US2012036459 W US 2012036459W WO 2012151468 A1 WO2012151468 A1 WO 2012151468A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- seq
- polypeptide
- complement factor
- factor
- Prior art date
Links
- 108090000056 Complement factor B Proteins 0.000 title claims abstract description 405
- 102000003712 Complement factor B Human genes 0.000 title claims abstract description 404
- 235000001014 amino acid Nutrition 0.000 claims abstract description 331
- 238000000034 method Methods 0.000 claims abstract description 105
- 230000024203 complement activation Effects 0.000 claims abstract description 103
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 93
- 229920001184 polypeptide Polymers 0.000 claims abstract description 84
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 84
- 230000035772 mutation Effects 0.000 claims abstract description 83
- 239000013598 vector Substances 0.000 claims abstract description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 55
- 201000010099 disease Diseases 0.000 claims abstract description 53
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 45
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 44
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 44
- -1 free cysteine amino acid Chemical class 0.000 claims abstract description 23
- 150000001413 amino acids Chemical class 0.000 claims description 338
- 229940024606 amino acid Drugs 0.000 claims description 323
- 108090000623 proteins and genes Proteins 0.000 claims description 278
- 102000004169 proteins and genes Human genes 0.000 claims description 254
- 235000018102 proteins Nutrition 0.000 claims description 247
- 210000004027 cell Anatomy 0.000 claims description 196
- 238000006467 substitution reaction Methods 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 75
- 102100022133 Complement C3 Human genes 0.000 claims description 67
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 67
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 61
- 230000027455 binding Effects 0.000 claims description 58
- 230000000295 complement effect Effects 0.000 claims description 54
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 38
- 230000001404 mediated effect Effects 0.000 claims description 37
- 235000018417 cysteine Nutrition 0.000 claims description 35
- 238000012217 deletion Methods 0.000 claims description 34
- 230000037430 deletion Effects 0.000 claims description 34
- 230000002401 inhibitory effect Effects 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 31
- 235000004279 alanine Nutrition 0.000 claims description 30
- 239000013603 viral vector Substances 0.000 claims description 30
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 29
- 229960002433 cysteine Drugs 0.000 claims description 29
- 239000007924 injection Substances 0.000 claims description 29
- 238000002347 injection Methods 0.000 claims description 29
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 28
- 229960003767 alanine Drugs 0.000 claims description 28
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 26
- 235000003704 aspartic acid Nutrition 0.000 claims description 26
- 229960005261 aspartic acid Drugs 0.000 claims description 26
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 26
- 101000710032 Homo sapiens Complement factor B Proteins 0.000 claims description 25
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 24
- 229960001230 asparagine Drugs 0.000 claims description 23
- 235000009582 asparagine Nutrition 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 23
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 22
- 239000004471 Glycine Substances 0.000 claims description 21
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 21
- 229960001153 serine Drugs 0.000 claims description 21
- 235000004400 serine Nutrition 0.000 claims description 21
- 208000002780 macular degeneration Diseases 0.000 claims description 20
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 19
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 16
- 102000012479 Serine Proteases Human genes 0.000 claims description 15
- 108010022999 Serine Proteases Proteins 0.000 claims description 15
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 15
- 229960004441 tyrosine Drugs 0.000 claims description 15
- 235000002374 tyrosine Nutrition 0.000 claims description 15
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 14
- 108091005804 Peptidases Proteins 0.000 claims description 14
- 239000004365 Protease Substances 0.000 claims description 14
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 14
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 14
- 229960000310 isoleucine Drugs 0.000 claims description 14
- 108010009575 CD55 Antigens Proteins 0.000 claims description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 13
- 230000037431 insertion Effects 0.000 claims description 13
- 229960003136 leucine Drugs 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 13
- 229960005190 phenylalanine Drugs 0.000 claims description 13
- 229960004295 valine Drugs 0.000 claims description 13
- 239000004474 valine Substances 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 229960003121 arginine Drugs 0.000 claims description 12
- 206010003246 arthritis Diseases 0.000 claims description 12
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 229960002885 histidine Drugs 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 230000004075 alteration Effects 0.000 claims description 10
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 9
- 206010063837 Reperfusion injury Diseases 0.000 claims description 9
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 9
- 108010081667 aflibercept Proteins 0.000 claims description 9
- 230000010085 airway hyperresponsiveness Effects 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 230000003292 diminished effect Effects 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- 235000018977 lysine Nutrition 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 239000000539 dimer Substances 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- 206010030043 Ocular hypertension Diseases 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 150000001945 cysteines Chemical class 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229960002833 aflibercept Drugs 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 229940012356 eye drops Drugs 0.000 claims description 5
- 231100000562 fetal loss Toxicity 0.000 claims description 5
- 239000003862 glucocorticoid Substances 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 5
- 239000013607 AAV vector Substances 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 102000003706 Complement factor D Human genes 0.000 claims description 4
- 108090000059 Complement factor D Proteins 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 4
- 239000000262 estrogen Substances 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000008816 organ damage Effects 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 3
- 108010053085 Complement Factor H Proteins 0.000 claims description 3
- 102000016550 Complement Factor H Human genes 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 230000006044 T cell activation Effects 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 102400001047 Endostatin Human genes 0.000 claims description 2
- 108010079505 Endostatins Proteins 0.000 claims description 2
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
- 241000175212 Herpesvirales Species 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims description 2
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 claims description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 102400000709 T2-TrpRS Human genes 0.000 claims description 2
- 101800000458 T2-TrpRS Proteins 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047124 Vasculitis necrotising Diseases 0.000 claims description 2
- 208000036866 Vitreoretinopathy Diseases 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 229960003655 bromfenac Drugs 0.000 claims description 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 201000000159 corneal neovascularization Diseases 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- RPBJOYICBFNIMN-RDWMNNCQSA-M dexamethasone sodium m-sulfobenzoate Chemical compound [Na+].O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=CC(S([O-])(=O)=O)=C1 RPBJOYICBFNIMN-RDWMNNCQSA-M 0.000 claims description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960001048 fluorometholone Drugs 0.000 claims description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229960003101 pranoprofen Drugs 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000001359 rheumatologic effect Effects 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 206010040400 serum sickness Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 229960004492 suprofen Drugs 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 229960001017 tolmetin Drugs 0.000 claims description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 230000001133 acceleration Effects 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000014509 gene expression Effects 0.000 description 76
- 230000037361 pathway Effects 0.000 description 41
- 239000000243 solution Substances 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 238000009472 formulation Methods 0.000 description 26
- 239000000872 buffer Substances 0.000 description 25
- 239000006143 cell culture medium Substances 0.000 description 23
- 230000002949 hemolytic effect Effects 0.000 description 23
- 239000012528 membrane Substances 0.000 description 23
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 22
- 210000004379 membrane Anatomy 0.000 description 22
- 230000001105 regulatory effect Effects 0.000 description 22
- 210000000130 stem cell Anatomy 0.000 description 21
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 20
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 20
- 108091026890 Coding region Proteins 0.000 description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 229960002449 glycine Drugs 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000008363 phosphate buffer Substances 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 238000001994 activation Methods 0.000 description 15
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 14
- 229920002873 Polyethylenimine Polymers 0.000 description 14
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 14
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 14
- 235000011130 ammonium sulphate Nutrition 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 102000004856 Lectins Human genes 0.000 description 11
- 108090001090 Lectins Proteins 0.000 description 11
- 230000004154 complement system Effects 0.000 description 11
- 239000002523 lectin Substances 0.000 description 11
- 230000001603 reducing effect Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 239000012228 culture supernatant Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 9
- 238000013019 agitation Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000008588 hemolysis Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- 238000011210 chromatographic step Methods 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 229960004799 tryptophan Drugs 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 7
- 102100026553 Mannose-binding protein C Human genes 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960002989 glutamic acid Drugs 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229940076783 lucentis Drugs 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108010005642 Properdin Proteins 0.000 description 6
- 102100038567 Properdin Human genes 0.000 description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 235000004554 glutamine Nutrition 0.000 description 6
- 229960002743 glutamine Drugs 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 4
- 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 230000004988 N-glycosylation Effects 0.000 description 4
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 4
- 206010038934 Retinopathy proliferative Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000011191 terminal modification Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 102000000989 Complement System Proteins Human genes 0.000 description 3
- 108010069112 Complement System Proteins Proteins 0.000 description 3
- 102100030886 Complement receptor type 1 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100025169 Max-binding protein MNT Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001775 bruch membrane Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 229960003876 ranibizumab Drugs 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001092142 Molina Species 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101710109723 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 239000004074 complement inhibitor Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003014 totipotent stem cell Anatomy 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010034358 Classical Pathway Complement C3 Convertase Proteins 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 108010028771 Complement C6 Proteins 0.000 description 1
- 102100024339 Complement component C6 Human genes 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 101150072419 F12 gene Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000251728 Gnathostomata <vertebrate> Species 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 108700031312 Membrane Cofactor Proteins 0.000 description 1
- 102000050019 Membrane Cofactor Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000016999 Parasitic Lung disease Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 1
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 101150105073 SCR1 gene Proteins 0.000 description 1
- 101150097162 SERPING1 gene Proteins 0.000 description 1
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 229940088949 cinryze Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 201000004897 cough variant asthma Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940052354 dibasic sodium phosphate heptahydrate Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 108010011867 ecallantide Proteins 0.000 description 1
- 229960001174 ecallantide Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229940050762 firazyr Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 108700023918 icatibant Proteins 0.000 description 1
- 229960001062 icatibant Drugs 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000036273 reactive airway disease Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102200088234 rs786200925 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the complement system is a component of the innate and adaptive immune system (reviewed by Volanakis, J.E., 1998. Chapter 2. In The Human Complement System in Health and Disease. Edited by J. E. Volanakis, and M.M. Frank. Marcel Dekker, Inc., New York pp 9-32). Complement plays an important role in microbial killing, and for the transport and clearance of immune complexes. Many of the activation products of the complement system are also associated with proinflammatory or immunoregulatory functions.
- the complement system consists of plasma and membrane-associated proteins that are organized in three enzymatic-activation cascades: the classical, the lectin, and the alternative pathways
- complement activation is initiated either by specific antibodies recognizing and binding to a variety of pathogens and foreign molecules, and/or by direct interaction of complement proteins with foreign substances.
- these pathways result in the fomiation of protease complexes, the C3-convertases.
- the classical pathway C3- convertase, C4b2a, and the alternative pathway C3-convertase, C3bBb, are both able to cleave the a chain of C3 generating C3b.
- C3b has the potential to bind covalently to biological surfaces.
- C3b binding leads to opsonization for phagocytosis by
- the C3- convertases can function as C5-convertases, cleaving C5 and initiating the assembly of the TCC, or membrane attack complex (MAC), which mediates cellular lysis by insertion of pore-forming protein complexes into targeted cell membranes.
- MAC membrane attack complex
- MBLs and ficolins both of which are characterized by the presence of a collagen- like domain, like Clq, and a carbohydrate binding domain having a common binding specificity for GlcNAc.
- MASPs and Clr/Cl s share the same domain organization and form a subfamily of serine proteases.
- the lectin complement pathway in innate immunity is closely related to the classical complement pathway in adaptive immunity, e.g., with respect to the structures and functions of their components. Both pathways are typically initiated by complexes consisting of collagenous proteins and serine proteases of the mannose-binding lectin (MBL)-associated serine protease (MASP)/Clr/Cls family. It has been speculated that the classical pathway emerged evolutionarily after the lectin pathway.
- MBL mannose-binding lectin
- MASP mannose-binding lectin-associated serine protease
- Activation of the alternative complement pathway typically begins when C3b protein (or C3i) binds to a cell and other surface components, e.g., of microbes. C3b can also bind to immunoglobulin G (IgG) antibodies.
- Alternative pathway Factor B protein then combines with the C3b protein to form C3bB.
- Factor D protein then splits the bound Factor B protein into fragments Bb and Ba, forming C3bBb.
- Properdin then binds to the Bb to form C3bBbP that functions as a C3 convertase capable of enzymatically splitting typically hundreds of molecules of C3 into C3a and C3b.
- Some of the C3b subsequently binds to some of the C3bBb to form C3bBbC3b, a C5 convertase capable of splitting molecules of C5 into C5a and C5b.
- C3b Since C3b is free in the plasma, it can bind to either a host cell or pathogen surface. To prevent complement activation from proceeding on the host cell, there are several different kinds of regulatory proteins that disrupt the complement activation process.
- Complement Receptor 1 (CR1 or CD35) and DAF (also known as CD55) compete with Factor B in binding with C3b on the cell surface and can even remove Bb from an already formed C3bBb complex.
- the formation of a C3 convertase can also be prevented when a plasma protease called Factor I cleaves C3b into its inactive form, iC3b.
- Factor I works with C3b-binding protein cofactors such as CR1 and Membrane Cofactor of Proteolysis (MCP or CD46).
- Another complement regulatory protein is Factor H which either competes with factor B, displaces Bb from the convertase, acts as a cofactor for Factor I, or preferentially binds to C3b bound to vertebrate cells.
- the precise function of the complement system depends on its regulation, as activation of the complement cascade leads to the production of a number of proteins that contribute to inflammation. This is beneficial when contributing to a host defense, but can be detrimental if activated on self tissue. Typically, activation of C3 in the blood is kept at a low level, and C3b deposition is limited to the surface of pathogens.
- the human wild type complement factor B protein is a 764 amino acid, single-chain glycoprotein (approximately 93-kDa) composed of five protein domains (Mole et al, 1984 The J. Biol Chem, 259:6, 3407-3412).
- a human wild type complement factor B protein (ffl) is typically expressed with an N-terminal 25 amino acid signal peptide, e.g., see SEQ ID NO: 1.
- the amino- terminal region (Ba) of human wild type complement factor B protein consists primarily of three short consensus repeats. The middle region is a type A domain similar to those found in von Willebrand factor (Colombatti et al., Blood (1991) 77(11):2305- 15).
- SP serine protease
- Complement factor B analogs and their use for inhibiting complement and treating complement mediated diseases are described in PCT Publication No. WO08/106644 and U.S. Patent Publication No. US20100120665.
- the human complement factor B protein analog, hfB3 (described in U.S. Patent Publication No. 20100120665), is a dominant negative human factor B protein variant that efficiently inhibits the alternative complement (AP) activity.
- hfB3 protein (SEQ ID NO:4) has five amino acid changes compared to a human wild type factor B protein (SEQ ID NO: 1).
- hfB3 protein The five amino acid changes enable hfB3 protein to (i) bind much tighter to C3b protein, (ii) resist C3b-dependent cleavage by factor D protein, and (iii) bind tighter to factor D protein when compared to the wild type factor B protein.
- the tighter binding of hfB3 protein with C3b protein and factor D protein sequester two essential components of the alternative complement pathway (ACP) in an inactive C3 convertase (hfB3), blocking the AP activity.
- ACP alternative complement pathway
- C3b-bound hfB3 protein cannot be cleaved by factor D protein, the conformational change of hfB3 protein does not occur and the serine protease at the C-terminus of hfB3 protein is not activated.
- Both human wild type complement factor B protein and hfB3 contain 23 cysteine amino acids.
- the "active" forms of both have all of the cysteines forming disulfide bonds with one of the other cysteines, with the exception of the cysteine corresponding to the C292 of SEQ ID NO: 1.
- the C292 of the "active forms" of hfB3 and wild type factor B is a free cysteine (Parkes et al. 1983 Biochem J. 213, 201-209) and is highly conserved among various mammalian species, e.g. , see Table 1, below. Citation or discussion of a reference herein shall not he construed as an admission that such is prior art to the present invention.
- the invention provides polypeptides comprising a complement factor B analog.
- the invention also provides various complement factor B analogs.
- a complement factor B analog comprises a mutation of a free cysteine amino acid.
- the invention also provides nucleic acids and viral vectors comprising a nucleotide sequence encoding polypeptides and complement factor B protein analogs of the invention.
- Some embodiments of the invention provide cells, wherein the cells comprise a nucleic acid encoding a complement factor B protein analog of the invention and wherein the cells express a complement factor B protein analog.
- the invention provides pharmaceutical preparations comprising a polypeptide or complement factor B protein analog of the invention, a nucleic acid of the invention, a viral vector of the invention or any combination thereof.
- Also provided by the present invention are methods of treating a complement- mediated disease comprising administering to a patient a pharmaceutical preparation of the invention, a polypeptide of the invention, a complement factor B protein analog of the invention, a nucleic acid of the invention, a viral vector of the invention or any combination thereof.
- the invention also provides methods of producing a polypeptide comprising a complement factor B protein analog, the method comprising: expressing in a cell a complement factor B protein analog of the invention and purifying said complement factor B protein analog.
- Polypeptides of the invention can be used to modulate a complement pathway and for the study and/or treatment of various conditions or diseases related to a complement pathway.
- the invention is based on the findings that mutation or removal of a free cysteine (i) improves the yield of an active and/or properly folded complement factor B protein analog (e.g., see Examples 9 and 10); (ii) enhances the thermostability of a complement factor B protein analog (e.g. , see Examples 13 and 14); and/or (iii) reduces aggregation of a complement factor B protein analog (e.g. , see Example 6).
- This summary of the invention does not necessarily describe all features or necessary features of the invention. The invention may also reside in a sub-combination of the described features.
- Figure 1A depicts the classical and lectin complement pathways.
- the classical pathway is initiated through C 1 while the lectin pathway is initiated through mannose binding lectin (MBL).
- C4bC2a is a protease that cleaves C3 to C3a and C3b and is termed the C3 convertase.
- C4bC2aC3b cleaves C5 to C5a and C5b and is termed the C5 convertase.
- C3a, C4a, and C5a have inflammatory properties and attract phagocytotic cells.
- C5b6-9 forms the membrane attack complex (MAC), which creates membrane pores that kill infectious agents but can also damage host cells.
- MASP is mannan-binding lectin associated serine protease.
- Figure IB depicts the alternative complement pathway. This pathway is
- C3b binds to complement factor B (fB).
- This complex is then cleaved by complement factor D (fD) to yield C3bBb.
- Spontaneous dissociation ("decay") of this complex within minutes leads to its inactivation, whereas stabilization by properdin generates a complex that cleaves C3; that is, a C3 convertase.
- C3b participates in the C3 convertase to generate additional C3b thereby creating a positive feedback loop as shown by the large arrow.
- C3bBb is a C3 convertase.
- C3bBbC3b is a C5 convertase.
- Figure 2 is a hfB3-292S expression construct.
- CMV-cytomegalovirus immediate early promoter IRES-internal ribosomal entry site; Neo-neomycin phosphotransferase gene; SynPolyA-synthetic polyA; Amp-Ampicillin-resistant gene.
- SEQ ID NO: 8 is the nucleotide sequence of the hfB3-292S expression construct shown in Figure 2.
- Figure 3 shows Western blot analysis of raw cell culture supernatants containing either hfB3 or hfB3-292S protein after cell culture incubation for 72 hour (2 x 10 6 cells/mL).
- Lane 1 one ⁇ of cell culture medium from naive un-transfected 293 FreeStyle cells served as a negative control;
- Lane 2, one hundred ng of human wild type factor B (Quidel, Santa Clara, CA) purified from plasma served as a positive control;
- Lane 3 one ⁇ of cell culture medium from hfB3 producing cells;
- Lane 4 one ⁇ of cell culture medium from hfB3-292S producing cells.
- the molecular weight markers in KDa are indicated on the right.
- Figure 4 shows the results of a hemolytic assay. These results demonstrate inhibition of human alternative complement pathway hemolytic activity by raw hfB3 protein or hfB3- 292S protein producing cell culture medium. The relative hemolytic activity is scored by hemoglobin released after hemolysis of rRBCs by human alternative complement pathway activity.
- factor B-depleted human serum supplemented with 0 ⁇ g of purified human factor B protein (control, no lysis of rRBCs); factor B-depleted human serum supplemented in each reaction with a mixture of 0.5 ⁇ g of purified human factor B protein and 1.0, 0.5, 0.25 or 0.125 ⁇ of hfB3 protein or hfB3-292S protein, as indicated, from the culture medium of hfB3 protein or hfB3-292S protein producing cells. Note: 100% inhibition represented no lysis of rRBCs.
- the Y-axis represents mean OD405 and Standard Deviation (SD).
- Figure 5A shows hfB3 protein (200 ng), purified from a three step chromatography process, subjected to SDS-PAGE and silver staining analysis.
- Figure 5B shows inhibition of human alternative complement pathway hemolytic activity by the purified hfB3 protein.
- X- axis from left to right factor B protein-depleted human serum supplemented with 0 ⁇ g of purified wild type human factor B protein (wt hfB) (control, no lysis of rRBCs); factor B protein-depleted human serum supplemented in each reaction with a mixture of 0.5 ⁇ g of purified wild type human factor B protein and 1.0, 0.5, 0.3, 0.2, 0.1 or 0.05 ⁇ g of hfB3, as indicated. 100% inhibition represents no lysis of rRBCs.
- the Y-axis represents mean OD405 and SD.
- Figure 6 shows biological activity of two populations of hfB3 protein. Shown are the results for hydrophobic interaction chromatography (HIC) purified hfB 3 protein from Peak I and Peak II for inhibition of human alternative complement pathway hemolytic activity.
- X- axis from left to right factor B protein-depleted human serum supplemented with 0 ⁇ g of purified human factor B protein (control, no rRBCs lysis); factor B protein-depleted human serum supplemented in each reaction with a mixture of 0.5 ⁇ of purified wild type human factor B protein and various amounts of hfB3 protein ranging from 1.0 to 0.05 ⁇ g. 100% inhibition represents no lysis of rRBCs.
- the Y-axis represents mean OD405 and SD.
- Figure 7 shows reverse phase high-pressure liquid chromatography (HPLC) of raw cell culture supernatants containing either hfB3 protein or hfB3-292S protein after tissue culture incubation for 72 hours (2xl0 6 cells/mL).
- HPLC high-pressure liquid chromatography
- Figure 8 shows analysis of hfB3-Fc protein expression by subjecting 2 ⁇ of cell culture supernatant containing hfB3-Fc protein to a non-reducing SDS-PAGE and Western blot analysis. (See Example 12) Two bands of hfB3-Fc protein were detected with molecular weight markers in KDa indicated on the left.
- Figure 9 shows representative H&E staining of paraffin sections of the right front paw joints of mice from a study testing hfB3-292S in a collagen antibody-induced arthritis
- CAIA human model for rheumatoid arthritis as described in Example 16.
- Group 1 is the vehicle control group that received no collagen antibody cocktail.
- Group 2 is the untreated group that received the collagen antibody cocktail.
- Group 3 is the treated group that received the collagen antibody cocktail and was treated with hfB3-292S.
- Figure 10 shows joint swelling measurements from a study testing hfB3-292S in a collagen antibody-induced arthritis (CAIA) mouse model for rheumatoid arthritis as described in Example 16.
- the groups are the same as those in Figure 8, as described in the paragraph.
- hfB3-292S caused a statistically significant (p ⁇ 0.0003) reduction in joint swelling as compared to the untreated group (Group 2).
- FIG 11 shows a Western blot analysis of cell culture medium from cells transfected with an hfB3-292SN480 expression construct. This Western blot analysis was performed using a monoclonal antibody specific for hfB3-292S. The left lane contains hfB3-292S and the right lane is cell culture medium from cells transfected with an hfB3-292SN480 expression construct. The analysis detected a band of approximately 55 KDa from the cell culture medium of hfB3-292SN480 cell line (right lane).
- Figure 12 shows a Western blot analysis of cell culture medium from cells transfected with an hfB3-292S/Fc-mono expression construct as described in Example 19, below. A band of approximately 115 KDa was detected by purified goat anti-human factor B antibody from this non-reducing SDS-PAGE.
- Figure 13 shows the cell culture supernatant from cells expressing hfB3-292SN480 inhibited the human alternative complement pathway hemolytic activity in a dose dependent manner.
- Figure 14 shows the cell culture supernatant from cells expressing hfB3-292S/Fc- mono inhibited the human alternative complement pathway hemolytic activity in a dose- dependent manner.
- SEQ ID NO:2 amino acid sequence of a human complement factor B protein analog, hfB3-292S, which comprises the following mutations: K258A, R259A, K260A, D279G, N285D and C292S.
- SEQ ID NO: 3 amino acid sequence of a human complement factor B analog, hfB3-292S-740N, comprising the following mutations as compared to SEQ ID NO: 1 :
- SEQ ID NO:4 amino acid sequence of a human complement factor B analog, hfB3, which comprises the following mutations as compared to SEQ ID NO:l: K258A, R259A, K260A, D279G and N285D.
- SEQ ID NO:8 nucleotide sequence of an hfB3-292S expression construct, the construction of which is described in Example 2.
- SEQ ID NO: 9- 14 partial amino acid sequences of complement factor B proteins from a human, a mouse, a rat, a pig, a monkey and a sheep, respectively.
- SEQ ID NO: 17 amino acid sequence of a human complement factor B protein analog, hfB4.
- SEQ ID NO: 18 nucleotide sequence of an hfB3-Fc expression construct, the construction of which is described in Example 12.
- SEQ ID NO: 19-20 primers for site directed mutagenesis.
- SEQ ID NO:21 amino acid sequence of a human complement factor B protein analog, hfB3-Fc.
- SEQ ID NO:22 amino acid sequence of a human complement factor B protein analog, hfB3-292S-Fc.
- SEQ ID NO:23 amino acid sequence of a human complement factor B protein analog, hfB3-292S-740N-Fc.
- SEQ ID NO:24 nucleotide sequence of an expression construct for expressing hfB3-292SN480.
- hfB3 During production and purification of the complement factor B protein analog designated hfB3 (SEQ ID NO:4), two populations of the complement factor B protein analog were detected. One population had the desired activity for the complement factor B protein analog (Peak I) while the other population had substantially less of the desired activity (Peak II), e.g. , see Figure 6 and 7. The results from characterization of the two populations suggested that the two populations differed in their disulfide bond patterns. When the free cysteine (position 292 of SEQ ID NO:4) was mutated to a serine, Peak II was undetectable. Figure 6 shows that the Peak II fraction exhibits some ability to inhibit
- the cysteine corresponding to position 292 of SEQ ID NO: l is highly conserved among complement factor B proteins of different mammalian species (e.g. , see Table 1). Highly conserved sequences are typically important to the function of a protein.
- the neutral theory of molecular evolution states that mutations in amino acids occur in a stochastically constant manner as long as the mutations have no effect on the function of the gene product [Kimura M: The neutral theory of molecular evolution. Sci Am 1979, 241(5):98-100, 102, 108 passim].
- amino acids that are important for protein function and structure cannot mutate without a detrimental effect on protein activity. Therefore, these amino acids will change very slowly in a given protein family during evolution.” (Liu et al. BMC Bioinformatics 2006, 7:37)
- the less active population (Peak II fraction) of hfB3 protein could be the result of misfolding of hfB3 protein. It is possible that the generation of the majority of Peak II population was due to the combination of the free cysteine and the mutations introduced to hfB3 protein because when cells were engineered to express a wild-type human complement factor B protein (SEQ ID NO: 1) in a manner similar to that used for hfB3 protein, only one population of the wild-type human factor B protein was detected (data not shown).
- This mutation of a free cysteine allows for a higher yield of the active complement factor B analog since most, if not all, of the produced complement factor B protein analog is in an active form. Additionally, mutation of a free cysteine results in a more stable protein since all of the remaining unmutated cysteines are part of a disulfide bond and there is no free cysteine left that can participate in possibly undesirable and detrimental reactions.
- WO08/106644 or U.S. Patent Publication No. US20100120665 can have their free cysteine mutated and still retain their desired function, while benefiting from the aforementioned advantages of the mutation. Therefore, the present invention includes any of the complement factor B protein analogs described in PCT Publication No. WO08/106644 or U.S. Patent Publication No. US20100120665 with a mutation of a free cysteine.
- free cysteine refers to a cysteine that is part of a protein or a peptide, wherein the free cysteine does not form a disulfide bond with another cysteine in the same protein or peptide.
- a "free cysteine" of a protein analog does not form a disulfide bond with another cysteine (in the same protein or peptide) when the protein analog has a desired activity, but may form a disulfide bond with another cysteine (in the same protein or peptide) in a less active or inactive form of the protein analog.
- complement-mediated refers to a process or disease that involves complement.
- a “complement-mediated” disease or condition is one wherein complement activity is one of the underlying causes of the disease or condition and wherein inhibition or blocking of the complement activity lessens the extent of the disease or condition. Examples of numerous complement-mediated diseases or conditions are described herein.
- wildtype (or wild-type), which is used interchangeably with “native”, relates to a naturally occurring protein encoded by a mammalian genome, a naturally occurring nucleic acid, and so on. In some cases, there may be actually more than one protein corresponding to the wild-type version, e.g. , due to allelic differences; different isoforms; and/or genetic variation among different individuals of a species.
- analog refers to a structural derivative of a protein (parent protein). An analog does not necessarily retain all of the properties of the parent protein and in some cases has at least one altered property as compared to the corresponding native parent protein. In some embodiments, a parent protein is a native (naturally-occurring) protein.
- an analog or variant protein is produced by replacing, substituting, deleting, and/or adding amino acids with regard to the corresponding native amino acid sequence of the protein.
- the substitutions or insertions typically involve naturally occurring amino acids, but may also include synthetic or unconventional amino acids as well.
- an analog or variant is produced by mutating a protein, e.g. , mutating a nucleic acid encoding it.
- An analog will typically retain at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% of the
- Analogs also include fragments of full length analogs that comprise a portion of the amino acid sequence and either retain one or more biological activities of the parent protein or of a full length analog or inhibit one or more of these biological activities.
- an amino acid in a particular protein refers to the particular amino acid in that particular protein and also to an amino acid in a related or similar protein and may provide a similar function to the protein.
- an amino acid in a human complement factor B may be found to correspond with an amino acid in a murine complement factor B or in a human allelic variant of factor B, usually determined by aligning the two amino acid sequences.
- one skilled in the art can align two or more related sequences, such as SEQ ID NOs:9- 14, to determine corresponding amino acids, e.g. , using a BLAST program (e.g. , see Table 1, above).
- corresponding amino acids can be determined, e.g. , by aligning motifs (e.g. , a protease cleavage motif) within related or unrelated proteins. Such an alignment may also be used to derive consensus sequences of target protein or domains thereof.
- gene typically refers to a coding region for a protein.
- gene is also referring to elements (e.g. , regulatory elements) operatively linked to a coding region such as promoters, enhancers, splice sites (acceptors and/or donors), polyadenylation signals, introns, 5' untranslated regions, 3' untranslated regions, etc.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in humans.
- a "therapeutic benefit” is not necessarily a cure for a particular disease or condition (including any disease or condition described herein), but rather, encompasses a result which most typically includes alleviation of the disease or condition, elimination of the disease or condition, reduction of one or more symptoms associated with the disease or condition, prevention or alleviation of a secondary disease or condition resulting from the occurrence of a primary disease or condition, diminishing the likelihood of developing a condition or disease, diminishing the severity of a disease or condition, changing the character of a disease or condition, shortening the course of a disease or condition, slowing or preventing the progression or worsening of a disease or condition, and/or prevention of the disease or condition.
- the present invention includes complement factor B protein analogs and polypeptides comprising complement factor analogs and their uses.
- Some embodiments of the invention include a complement factor B protein analog wherein a free cysteine has been mutated.
- this mutation of a free cysteine can comprise a deletion of the free cysteine or substitution of the free cysteine with another amino acid(s).
- a free cysteine can be substituted with essentially any amino acid, that still allows for the complement factor B protein analog to retain at least some of the desired characteristic(s), such as the ability to downregulate, diminish or ablate complement activity.
- a substitution may be with one or more amino acids.
- a free cysteine is substituted with a serine.
- a free cysteine is substituted with one or more amino acids selected from the group consisting of alanine, histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tyrosine and valine.
- a free cysteine corresponds to amino acid 292 of SEQ ID NO.l.
- the invention provides complement factor B protein analogs that do not comprise a free cysteine.
- the invention also provides methods of making or producing a complement factor B protein analog comprising mutating a free cysteine.
- Mutation of a free cysteine can be combined with other mutations of a complement factor B protein, e.g. , other mutations as described herein.
- the invention also provides complement factor B protein analogs wherein the cysteine corresponding amino acid 292 of SEQ ID NO: l is mutated.
- This mutation can be a deletion, insertion or substitution, such as a serine substitution or other mutations as described herein.
- Analogs can include various muteins of a sequence other than the naturally-occurring amino acid sequence. For example, single or multiple amino acid substitutions (e.g. , conservative or non-conservative amino acid substitutions) may be made in the naturally- occurring sequence.
- a conservative amino acid substitution generally should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art- recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J.
- Conservative substitutions include, but are not limited to, those from the following groupings: Acidic Residues Asp (D) and Glu (E); Basic Residues Lys (K), Arg (R), and His (H); Hydrophilic Uncharged Residues Ser (S), Thr (T), Asn (N), and Gin (Q); Aliphatic Uncharged Residues Gly (G), Ala (A), Val (V), Leu (L), and lie (I); Non-polar Uncharged Residues Cys (C), Met (M), and Pro (P); Aromatic Residues Phe (F), Tyr ( ⁇ ), and Trp (W); Alcohol group-containing residues S and T; Aliphatic residues I, L, V and M; Cycloalkenyl-associated residues F, H, W and Y;
- a non-conservative substitution is used.
- mutations include, but are not limited to, substitutions of one or more amino acids, deletions of one or more amino acids or insertions of one or more amino acids. Mutations include, but are not limited to, those which: ( 1) reduce susceptibility of the complement factor B analog to proteolysis, (2) reduce susceptibility of the complement factor B analog to oxidation, (3) alter binding affinity of the complement factor B analog for forming protein complexes, (4) alter (e.g. , increase or decrease) binding affinities of the complement factor B analog, (5) reduce immunogenicity of the complement factor B analog; (6) increase stability (e.g. , thermostability ) of the complement factor B analog; (7) reduce aggregation of the complement factor B protein analog; or any combinations of 1-7.
- a human complement factor B analog of the invention competes with binding of native complement factor B.
- native complement factor B can bind with complement factor C3b to form C3bB, e.g. , see Figure IB.
- Factor B that is part of the C3bB complex can bind factor D. Therefore, in some embodiments, a complement factor B analog of the invention can compete with the binding of a native factor B for (i) binding to C3b, (ii) binding to factor D or (iii) both.
- a complement factor B protein analog of the invention is an analog of SEQ ID NO:4 having cysteine amino acids that form disulfide bonds and a free cysteine amino acid that has been substituted by another amino acid, more than one amino acid or has been deleted with no substitution.
- a complement factor B protein analog has increased C3b binding affinity as compared to a corresponding native complement factor B protein and the complement factor B protein analog comprises (i) diminished protease activity as compared to a corresponding native complement factor B protein; (ii) diminished ability to be cleaved by factor D protein as compared to a corresponding native complement factor B protein; or (iii) diminished protease activity as compared to a corresponding native complement factor B protein and diminished ability to be cleaved by a factor D protein as compared to a corresponding native complement factor B protein.
- a complement factor B analog comprises a mutation in the C3b binding domain and the complement factor B protein analog exhibits increased binding affinity to C3b as compared to the binding affinity of a corresponding native complement factor B protein to C3b.
- a mutation in the C3b binding domain comprises (i) a substitution or deletion of an aspartic acid corresponding to amino acid 279 of SEQ ID NO: l, a substitution or deletion of an asparagine corresponding to amino acid 285 of SEQ ID NO: l or both; or (ii) an insertion of at least one amino acid next to said aspartic acid or said asparagine. In some embodiments, this aspartic acid, asparagine or both are substituted with one or more amino acids.
- an aspartic acid corresponding to amino acid 279 of SEQ ID NO: l is substituted with glycine, alanine or asparagine. In some embodiments, an asparagine corresponding to amino acid 285 of SEQ ID NO: l is substituted with glycine, alanine, or aspartic acid. In some embodiments, an aspartic acid corresponding to amino acid 279 of SEQ ID NO: l is substituted with glycine and an asparagine corresponding to amino acid 285 of SEQ ID NO: l is substituted with aspartic acid.
- a complement factor B protein analog is a human complement factor B protein analog, based on a human complement factor protein.
- the instant invention includes complement factor B protein analogs, e.g., that can be delivered as proteins and/or via gene transfer to attenuate the alternative pathway of complement activation. These analogs may overcome hurdles that impede the development of some complement inhibitors including, for example: 1) avoiding long term systemic immune suppression; 2) achieving efficacy in the face of otherwise prohibitively high levels of complement factors in the blood; 3) achieving sufficient levels and distribution of the therapeutic complement factor B protein analog in the proximity of the retina and Bruch's membrane for efficacy; 4) achieving activity of the therapeutic complement factor B protein analog within drusen; 5) achieving sufficient duration of therapeutic delivery to treat a chronic disease; 6) achieving efficacy without detrimentally interfering with the classical complement pathway activities in the back of the eye; and/or 7) avoiding or diminishing an immune reaction (e.g. , a local immune reaction) to the therapeutic.
- an immune reaction e.g. , a local immune reaction
- Attenuating the positive feedback loop in the alternative pathway is a means of down-regulating the entire alternative pathway.
- One suitable means for attenuating the alternative pathway feedback loop is to interfere with complement factor B (IB) protein function or levels.
- Some embodiments of the invention use a complement factor B analog for attenuating complement activity.
- a complement factor B protein analog of the invention may comprise at least one mutation corresponding to a mutation of SEQ ID NO: 1 selected from the group consisting of K258A, R259A, K260A, D279G, N285D and D740N. In some embodiments, it comprises mutations corresponding to K258A, R259A, K260A, D279G and N285D of SEQ ID NO: l. In some embodiments, a complement factor B protein analog comprises a mutation corresponding to D740N of SEQ ID NO: l.
- Factor B protein can be manipulated in a number of ways, e.g. , to inhibit or reduce activation of the alternative pathway.
- particular sites in factor B can be altered, for example, by site directed mutagenesis, so that the molecule no longer fully functions properly.
- the enzyme portion or domain, (e.g. , the protease domain, which is a serine protease) of the molecule can be altered so that the molecule no longer has enzymatic activity or has reduced enzymatic activity (e.g., reduced by at least 2 fold, 5 fold, 10 fold, 50 fold or 100 fold).
- a complement factor B protein analog comprises a mutation in the active site of the serine protease domain, wherein the mutation decreases or ablates the complement factor B protein analog's ability to cleave complement factor C3 as compared to a corresponding native complement factor B protein.
- this mutation comprises a deletion or a substitution of an aspartic acid corresponding to amino acid 740 of SEQ ID NO: 1.
- an aspartic acid (D), corresponding to amino acid 740 of SEQ ID NO: l is substituted with another amino acid such as asparagine (N), alanine (A), glutamic acid (E), serine (S), tyrosine(Y), or glycine (G).
- N asparagine
- A alanine
- E glutamic acid
- S serine
- G glycine
- N693, T694 and D740 may constitute or be part of the substrate binding site and H526, D576 and S699 may constitute or be part of the catalytic center, e.g. , see Xu et al., J Biol Chem. 2000 275(l):378-85.
- a factor B protein analog comprises a mutation of at least one of the amino acids selected from amino acids 739-746 of SEQ ID NO: l.
- a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 739 of SEQ ID NO: l with an alanine.
- a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 740 of SEQ ID NO: 1 with an amino acid selected from the group consisting of asparagine, glutamic acid, alanine, serine and tyrosine.
- a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 741 of SEQ ID NO: l with an amino acid selected from the group consisting of tryptophan and alanine. In some embodiments, a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 742 of SEQ ID NO: l with glutamine. In some embodiments, a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 743 of SEQ ID NO: l with phenylalanine. In some embodiments, a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 745 of SEQ ID NO: l with phenylalanine.
- a complement factor B protein analog comprises a substitution of the amino acid corresponding to amino acid 746 of SEQ ID NO: l with tryptophan or alanine.
- a factor B protein analog comprises a mutation of one or two of the amino acids 693 and 694 of SEQ ID NO: l , e.g. , a substitution or deletion.
- a factor B protein analog comprises a mutation of one or two of the amino acids 526, 576 and 699 of SEQ ID NO: I , e.g. , a. substitution or deletion.
- Other sites in factor B that can be altered include: 1) the binding site for properdin (the properdin binding domain) such that binding occurs with lower affinity (for example, such as 2 fold, 5 fold, 10 fold, 50 fold or 100 fold reduced affinity as compared to the wild type factor B protein) or with greater affinity (such as at least 2 fold, 5 fold, 10 fold, 50 fold or 100 fold increased affinity as compared to the wild type factor B); 2) the binding site for C3b protein (the C3b binding domain) such that binding occurs with lower affinity (such as at least 2 fold, 5 fold, 10 fold, 50 fold or 100 fold reduced affinity as compared to the wild type factor B protein) or with greater affinity (such as at least 2 fold, 5 fold, 10 fold, 50 fold or 100 fold increased affinity as compared to wild type factor B protein, for example, this may be achieved by substituting the amino acid corresponding to position 279 and/or position 285 of SEQ ID NO: l with other amino acids, for example, wherein the amino acid at the position corresponding to position 279 is substituted with asparagine
- a complement factor B protein analog comprises an alteration in the complement factor D cleavage site wherein the alteration decreases or ablates cleavage of the complement factor B protein analog by factor D protein.
- an alteration in the factor D cleavage site comprises (i) a substitution or deletion of an arginine corresponding to amino acid 259 of SEQ ID NO: l , a substitution or deletion of one or both lysines corresponding to amino acid 258 or 260 of SEQ ID NO: l or a substitution or deletion of the arginine and both lysines; or (ii) an insertion next to the arginine, next to the one or both lysines, or next to the arginine and one or both of the lysines.
- a complement factor B protein analog has amino acids corresponding to amino acids 258-260 of SEQ ID NO: l each replaced with alanine.
- the invention includes (i) complement factor B protein analogs that bind to both factors C3b and D; (ii) complement factor B protein analogs with increased binding (as compared to their native form) to both factors C3b and D; (iii) complement factor B protein analogs with increased binding (as compared to their native form) to factor D protein; and (iv) complement factor B protein analogs with increased binding (as compared to their native form) to C3bB complex.
- the invention also includes methods of inhibiting a complement pathway using the complement factor B protein analogs of the invention, such as i-iv, above.
- increased binding is increased by about 1.5 to about 10,000, about 10 to about 10,000, about 100 to about 10,000, about 1,000 to about 10,000, about 1.5 to about 1,000, about 1.5 to about 100, about 1.5 to about 10, about 2 to about 5, about 2 to about 10, about 5 to about 10, about 5 to about 20, about 10 to about 20, about 10 to about 30, about 20 to about 30, about 30 to about 50, about 50 to about 100, about 100 to about 500, about 500 to about 1,000, about 1,000 to about 5,000, or about 5,000 to about 10,000 fold. In some embodiments, increased binding is increased by greater than 1.5, 2, 3, 4, 5, 10, 50, 100, 500, 1000, 5000 or 10,000 fold.
- increased binding can be measured by immunoprecipitation or using a Biacore (GE Healthcare, Piscataway, NJ), e.g. , as compared to the wild type protein.
- binding could be measured by immunoprecipitation of the protein with a binding molecule for C3b protein and then detecting factor D protein in the immunoprecipitate, e.g. , using an immunoassay such as an ELISA or Western, for example, with increased binding demonstrated as a band of increased intensity in a Western.
- Some factor B protein analogs of the invention may have increased binding to C3b protein and/or factor D protein by a factor of 2 fold, 4 fold, 5 fold, 10 fold, 20 fold, 50 fold, 100 fold, 500 fold, 1000 fold as compared to binding of wild type factor B to C3b and/or factor D.
- increased binding can be measured by immunoprecipitation or using a Biacore (GE Healthcare, Piscataway, NJ).
- modified factor B protein analogs of the invention comprise one or more of the amino acid alterations discussed herein and additionally have one or more additional amino acid substitutions, insertions or alterations ⁇ e.g. , at least or no more than 1, 2, 5, 8, 10, 15 20, 50, 100, or 200 alterations), which analogs retain the increased binding to C3b and/or factor D or other biological activity of the factor B protein analogs discussed herein, which mediates inhibition of the complement pathway.
- Such analogs may have at least 99.9%, 99%, 98%, 95%, 90%, 85%, 80%, 75% or 70% amino acid sequence identity with a wild type factor B protein, for example, the amino acid sequence of SEQ ID NO: 1 and retain the increased binding to C3b and/or factor D.
- nucleic acid In the context of gene therapy and expression of complement factor B protein analogs, the alterations/mutations will be reflected at the level of the encoding nucleic acid. Thus, modifications also can be made to the nucleic acid to enhance expression. For example, certain codons may be preferred by a particular host cell. Thus, recoding can be performed where certain codons are preferred in, for example, a particular mammalian expression system or cell.
- Some embodiments of the invention are directed to polynucleotides and host cells (or host multicellular organisms) useful in the production of a complement factor B protein analog and directed to the analogs, e.g. , hfB3-292S (SEQ ID NO:2), hfB3-292S-740N (SEQ ID NO:3), hfB3-292S-Fc (SEQ ID NO:22), hfB3-292S-740N-Fc (SEQ ID NO:23) or hfB3- 292S/Fc-mono (SEQ ID NO:26).
- Methods of isolating and testing complement-mediated activity of these complement factor B protein analogs are also provided.
- Some aspects of the invention are directed to pharmaceutical compositions/preparations wherein a complement factor B protein analog is an active ingredients in a therapeutic and/or a prophylactic contexts. Some embodiments of the invention are also directed to methods of treating complement-mediated disorders using a therapeutically effective amount of a complement factor B protein analog.
- a complement factor B analog may comprise glycosylation patterns which are distinct from glycosylation patterns on a naturally-occurring complement factor B, or may lack glycosylation altogether.
- Carbohydrates may be added to and/or removed from factor B analogs comprising glycosylation site sequences for N- and/or O-linked glycosylation in vitro, such as with a canine pancreatic microsome system (e.g. , see Mueckler and Lodish (1986) Cell 44:629 and Walter, P. (1983) Meth. Enzymol. 96:84) or the like.
- a complement factor B analog of the invention may be produced comprising adding or deleting/mutating an amino acid sequence corresponding to a glycosylation site, e.g. , changing the glycosylation pattern/status of a protein can change functional characteristics of a protein.
- hfB2, hfB3 (SEQ ID NO:4), hfB3-292S (SEQ ID NO:2), MB3-292S- 740N (SEQ ID NO:3), hfB3-292S-Fc (SEQ ID NO:22), hfB3-292S-740N-Fc (SEQ ID NO:23) and hfB3-292S/Fc-mono (SEQ ID NO:26) comprise an N285D substitution, as compared to a wildtype factor B (SEQ ID NO: 1), which results in the removal of an N- glycosylation site.
- hfB2 and hfB3 complement factor B protein analogs are described in detail in U.S. Patent Publication No.
- the loss of the N- glycosylation site alters the characteristics of the protein.
- the same effect may be achieved by producing the protein in a cell that has an altered glycosylation pattern or that does not glycosylate this N285.
- a factor B protein or analog may be produced in an E. coli cell that does not glycosylate the N285.
- a complement factor B protein analog is produced in a cell ⁇ e.g. , an E. coli) that does not glycosylate an amino acid corresponding to a wildtype factor B protein that is typically glycosylated, e.g.,
- a native factor B protein from one species may have activity in a complement reaction/pathway from another species. Therefore, the present invention also includes complement factor B protein analogs from one species for inhibiting complement activity in another species.
- a complement factor B protein analog of the invention is PEGylated, e.g. , see Roberts et al , Advanced Drug Delivery Reviews 54(4):459-476 (2002); Veronese, Biomaterials 22(5):405-417 (2001); Fee and Alstine, Chemical Engineering
- Polyethylene glycol (PEG) can be attached to a complement factor B protein analog of the invention.
- PEG is attached with or without a multifunctional linker either through site-specific conjugation of the PEG (e.g. , to the N-terminus or to the C terminus of a complement factor B analog) or via epsilon amino groups present on lysine residues.
- linear or branched polymer derivatization that results in minimal loss of biological activity can be used.
- the degree of conjugation can be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to a complement factor B analog.
- unreacted PEG can be separated from PEG conjugates by size-exclusion and/or by ion exchange chromatography.
- the carboxy-terminus, the amino-terminus or both of a complement factor B analog are chemically modified.
- Amino-terminal modifications such as acylation (e.g., acetylation) or alkylation (e.g., methylation) and carboxy-terminal modifications such as amidation, as well as other terminal modifications, including cyclization, may be incorporated into various embodiments of the invention.
- Certain amino- terminal and/or carboxy-terminal modifications and/or peptide extensions (such as fused to a heterologous polypeptide, such as albumin, immunoglobulin or portion thereof, such as an immunoglobulin Fc domain) to the core sequence can provide advantageous physical, chemical, biochemical, and pharmacological properties, such as: enhanced stability, increased potency and/or efficacy, resistance to serum proteases, desirable pharmacokinetic properties, and others.
- a complement factor B protein analog of the invention comprises an immunoglobulin Fc domain, for example, a human immunoglobulin Fc domain.
- an Fc domain is C-terminal to the corresponding complement factor B analog amino acid sequence.
- an Fc domain comprises or consists of amino acids 766-990 of SEQ ID NO:21 or amino acids 766-1003 or 786-1003 of SEQ ID NO:26.
- an Fc domain is amino acids 1-239 or 2-239 of SEQ ID
- an Fc domain is a human Fc domain.
- an Fc domain is from an immunoglobin, e.g., an IgG such as IgG4.
- an Fc domain is capable of forming a dimer with another Fc domain.
- a complement factor B analog of the invention is capable of forming dimers (e.g., homologous dimers), such as, but not limited to, through interactions of Fc domains.
- a complement factor B analog does not form dimers or the majority of a complement factor B analog population/preparation is in the form of monomers.
- a complement factor B analog comprising an Fc domain does not form dimers or the majority of this complement factor B analog population/preparation is in the form of monomers.
- a complement factor B analog comprises an Fc domain that has one or mutations of a cysteine(s) in the Fc domain sequence, e.g., a cysteine involved in dimerization of the Fc domain.
- a Fc domain comprises a mutation of one or more cysteines corresponding to amino acids 17 and/or 20 of SEQ ID NO:27.
- a complement factor B analog comprises an Fc domain that has one or mutations of a free cysteine(s) in the Fc domain sequence.
- a cysteine(s) is substituted with an amino acid selected from the group consisting of histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tyrosine, and valine.
- a cysteine is deleted.
- an amino acid sequence linker is used between amino acid sequences for a complement factor B analog and an Fc region. In some embodiments, this linker is one amino acid, e.g., arginine.
- a polypeptide comprises both a truncated complement factor B analog and an Fc region such as comprising amino acids corresponding to amino acids 26- 480 of SEQ ID NO:2 and an Fc region.
- the invention further provides analogs which are fragments of a complement factor B protein or analog that contain at least a 20, 30, 50, 70, 100, 150, 200, 300, 400, 480, 500, 600 or 700 amino acid portion of the complement factor B protein or analog and/or comprises 1, 2 or 3 domains of the protein and have or retain one or more biological activities of the wild type complement factor B protein or analog and/or acts as an inhibitor of an aspect of the complement system (either the classical pathway, alternative pathway or both).
- an analog is fragment of a complement factor B protein or analog and the fragment has at least 99.5%, 99%, 98%, 95%, 90%, 85% or 62% identity with the corresponding amino acid sequence of a wild-type complement factor B.
- a complement factor B analog comprises a C-terminal truncation wherein the analog is truncated at or after (C-terminal to) an amino acid corresponding to amino acid 407, 427, 457, 477, 480, 484, 487, 507 or 527 of SEQ ID NOs: l , 2 or 4.
- a complement factor B analog comprises a C-terminal truncation wherein the analog is truncated at an amino acid between amino acids corresponding to amino acids 407- 487, 470-495 or 477-487 of SEQ ID NOs: 1, 2 or 4.
- a complement factor B analog of the invention does not comprise amino acids corresponding to amino acids 408-764, 428-764, 458-764, 478-764, 481-764, 485-764, 488-764, 507-764, 527-764 of SEQ ID NOs: 1, 2 or 4.
- truncation or fragmentation of a factor B protein or analog can create a free cysteine.
- a truncation can result in the deletion of one cysteine of a cysteine pair that forms a disulfide bond in a native complement factor B protein, thus creating a polypeptide that contains a cysteine, but does not contain its native cysteine "partner".
- the remaining cysteine of the pair may be mutated, e.g., substituted with another amino acid, such as an alanine, histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tyrosine and valine or the cysteine may be deleted, e.g., to eliminate possible undesired disulfide bonding.
- Analogs of the invention can be prepared by various techniques, including but not limited to, chemical synthesis or by expression of the recombinant analog.
- Nucleotide sequences for genes and coding regions encoding human factor B, as well as the amino acid sequences are known in the art.
- a gene encoding human factor B is found in NCBI Database Accession No. NG_000013.
- a coding sequence for a human factor B is found in NCBI Database Accession No. NM_001710 and an amino acid sequence for a human complement factor B preproprotein is found in NCBI Database Accession No. NP_001701 or P00751. Sequences from other animal species are also known in the art.
- the third SCR domain is located at positions 160-217 of this 761 amino acid preprotein, and the mature murine factor B protein spans positions 23- 761.
- the first 22 amino acids of mouse factor B protein comprises a signal sequence.
- a human factor B preprotein is a 764 amino acid protein (e.g. , see SEQ ID NO: 1) with a signal peptide spanning amino acid positions 1-25.
- the mature chain of factor B corresponds to positions 26-764 (e.g. , see SEQ ID NO: l).
- the three SCR regions of human factor B are SCR1, also known as Sushi 1, spanning from about position 35 to about position 100, SCR2, also known as Sushi 2, spanning from about position 101 to about position 160 and SCR3, also known as Sushi 3, spanning from about position 163 to about position 220.
- fB l contains a mutated amino acid in the factor B (fB) protease site.
- fB factor B
- This fB moiety binds C3b with normal affinity and kinetics, but when acted upon by factor D (fD) and stabilized by properdin, does not function as a protease and does not form a C3 convertase.
- fB l contains a substitution with N at an amino acid corresponding to amino acid 740 of SEQ ID NO: l (e.g., D740N).
- the second of these complement factor B analogs, termed fB2 alters the same amino acid as fB l, but in addition, alters two additional amino acids in the C3b binding domain
- substitutions at amino acids corresponding to amino acids 279 and 285 of SEQ ID NO: l which increase the binding affinity of fB2 to C3b, e.g. , D279G, N285D and D740N changes.
- the N285D substitution removes a putative N-glycosylation site.
- hfB3 The third of these complement factor B protein analogs, termed hfB3, combines the mutations that increase C3b binding from 1B2 with a mutation that knocks out the site for cleavage by factor D, particularly with substitutions at amino acids corresponding to residues 258, 259 and 260 of SEQ ID NO: l as well as substitutions at amino acids corresponding to residues 279 and 285, e.g., K258A, R259A, K260A, D279G and N285D changes. Cleavage of wild type fB by factor D activates the fB protease.
- hfB3 with its five amino acid changes, efficiently binds C3b but has minimal protease activity.
- hffi l, hfB2 and hfB3 are examples of human factor B analogs which can be further modified to complement factor B analogs of the present invention by mutating a free cysteine corresponding to amino acid 292 of SEQ ID NO: l , e.g., by substituting the cysteine with a serine, but the invention is not limited to these specific analogs.
- Some embodiments of the invention include any complement factor B analog that modulates a complement pathway and does not comprise a free cysteine.
- a complement factor B analog comprises, in addition to a mutated free cysteine, one or more mutations of amino acids corresponding to one or more of the following amino acids in SEQ ID NO: l : amino acid 258, 259, 260, 279, 285, 739, 740, 741, 742, 743, 744, 745 and 746.
- These one or more mutations can be a substitution or deletion of the amino acid or an addition of at least one amino acid next to or within 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids of the corresponding amino acids.
- this addition disrupts, changes, enhances or inhibits the function of the listed amino acid, e.g., disrupts its role (i) in cleavage of another protein ⁇ e.g. , 740), (ii) as a site of cleavage by another protein ⁇ e.g. , amino acids corresponding to residues 258, 259 and/or 260 of SEQ ID NO: l), or (iii) its role in binding another protein ⁇ e.g. , amino acids corresponding to residues 279 or 285 of SEQ ID NO: l).
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to one or more of amino acids corresponding to 258, 259 and/or 260 of SEQ ID NO: l , e.g. , with an amino acid selected from the group consisting of alanine, glycine, valine, leucine and isoleucine. Some embodiments of the invention comprise a deletion of an amino acid corresponding to one, two or three of amino acids corresponding to amino acids 258, 259 and/or 260 of SEQ ID NO: l. Some embodiments of the invention comprise at least one addition of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids immediately next to an amino acid corresponding to amino acids 258, 259 and/or 260 of SEQ ID NO: l.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 739 of SEQ ID NO: 1. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 739 of SEQ ID NO: l, e.g., with an amino acid selected from the group consisting of alanine, glycine, valine, leucine and isoleucine. Some embodiments of the invention comprise a deletion of an amino acid corresponding to the 739 amino acid of SEQ ID NO: 1.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 740 of SEQ ID NO: l, e.g., with an amino acid selected from the group consisting of glutamic acid, asparagine, alanine, serine, glycine and tyrosine.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 740 of SEQ ID NO: l with an amino acid selected from the group consisting of valine, leucine, isoleucine, threonine, cysteine, methionine, glutamine, phenylalanine, tyrosine, tryptophan, glutamic acid, asparagine, alanine, serine, glycine and tyrosine.
- Some embodiments of the invention comprise a deletion of an amino acid corresponding to the 740 amino acid of SEQ ID NO: 1.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 741 of SEQ ID NO: l, e.g., with an amino acid selected from the group consisting of tryptophan and alanine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 741 of SEQ ID ⁇ . ⁇ with an amino acid selected from the group consisting of alanine, glycine, valine, leucine and isoleucine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 741 of SEQ ID NO: l with an amino acid selected from the group consisting of tryptophan, tyrosine and phenylalanine. Some embodiments of the invention comprise a deletion of an amino acid corresponding to the 741 amino acid of SEQ ID NO: l .
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 742 of SEQ ID NO: l, e.g. , with a glutamine.
- embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 742 of SEQ ID NO: l with an amino acid selected from the group consisting of glutamine, glutamic acid, asparagine, and aspartic acid. Some embodiments of the invention comprise a deletion of an amino acid corresponding to amino acid 742 of SEQ ID NO: l.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 743 and/or 745 of SEQ ID NO: l, e.g. , with a phenylalanine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 743 and/or 745 of SEQ ID NO: l with an amino acid selected from the group consisting of phenylalanine, tyrosine and tryptophan. Some embodiments of the invention comprise a deletion of one or more of amino acids corresponding to amino acids 743, 744 and/or 745 of SEQ ID NO: 1.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 746 of SEQ ID NO: l , e.g., with an amino acid selected from the group consisting of tryptophan and alanine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 746 of SEQ ID NO: 1 with an amino acid selected from the group consisting of alanine, glycine, valine, leucine and isoleucine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 746 of SEQ ID NO: 1 with an amino acid selected from the group consisting of tryptophan, tyrosine and phenylalanine. Some embodiments of the invention comprise a deletion of an amino acid corresponding to amino acid 746 of SEQ ID NO: l.
- Some embodiments of the invention comprise the insertion or substitution of 1, 2, 3,
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 279 of SEQ ID NO: l , e.g., with an amino acid selected from the group consisting of glycine, alanine and asparagine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 279 of SEQ ID NO: l with an amino acid selected from the group consisting of glycine, alanine, valine, leucine and isoleucine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 279 of SEQ ID NO: l with an amino acid selected from the group consisting of asparagine, glutamic acid and glutamine.
- Some embodiments of the invention comprise a deletion of an amino acid corresponding to amino acid 279 of SEQ ID NO: 1. Some embodiments of the invention comprise the insertion or substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids immediately next to or in place of an amino acid corresponding to amino acid 279 of SEQ ID NO: l.
- Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 285 of SEQ ID NO: l , e.g., with an amino acid selected from the group consisting of alanine and aspartic acid. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 285 of SEQ ID NO: 1 with an amino acid selected from the group consisting of glycine, alanine, valine, leucine and isoleucine. Some embodiments of the invention comprise a substitution of an amino acid corresponding to amino acid 285 of SEQ ID NO: l with an amino acid selected from the group consisting of aspartic acid, glutamic acid and glutamine.
- Some embodiments of the invention comprise a deletion of the an amino acid corresponding to amino acid 285 of SEQ ID NO: l . Some embodiments of the invention comprise the insertion or substitution of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids immediately next to or in place of an amino acid corresponding to amino acid 285 of SEQ ID NO: l.
- Some embodiments of the invention comprise a substitution of the one or more of the amino acids corresponding to amino acids 279, 282, 283, 284 and 285 of SEQ ID NO: l .
- these amino acids are replaced with glycine, isoleucine, proline, histidine and aspartic acid, respectively.
- Some embodiments of the invention comprise mutations of the amino acids corresponding to 258, 259, 260, 279 and 285 of SEQ ID NO: l as described herein.
- the invention provides a factor B protein analog, that comprises the amino acid sequence of SEQ ID NO:2, 3, 21, 22, or 23 (optionally without any signal sequence, e.g. , amino acids 1-25 contained therein).
- factor B protein analogs can be used in methods of the invention.
- the invention includes complement factor B protein analogs that comprise a combination of the mutations (substitutions, deletions and additions) discussed herein.
- these complement factor B analogs retain one or more of the attributes of the hffl l, hfB2, hfB3, hfB3-292S or hfB3-292S-740N analogs or any other complement factor B analog discussed herein.
- the invention further provides analogs that are fragments (for example comprising one or more domains of a complement factor B protein having one or more of the amino acid mutations set forth herein) of these analogs that have one or more of the attributes of the analogs discussed above, e.g. , hfB3-292SN480.
- analogs may comprise additional amino acid substitutions, deletions or insertions (for example, conservative amino acid substitutions, truncations of the N-terminus or C-terminus, etc.) such that the analog has at least 99.5%, 99%, 98%, 95%, 90%, 85%, 80%, 75% or 75% identity with the corresponding wild-type complement factor B or, in the case of an analog comprising a fragment of complement factor B, the analog has at least 99.5%, 99%, 98%, 95%, 90%, 85%, 80%, 75% or 70% identity between the corresponding parts of the analog and wild-type complement factor B.
- the hfB3-292S and hfB3-292SN480 proteins contain the following key features from N-terminus to C-terminus: 1) factor B protein native signal sequence for efficient secretion out of mammalian expression cells such as human 293 cells, CHO cells, BHK cells; 2) a mutated C3b-dependent factor D protein cleavage site (changing amino acids from
- K258R259K260 to A258A259A260 3) a mutated C3b protein binding site (changing amino acid from D279 to G279; and amino acid from N285 to D285) to enable its tight binding with and trapping of C3b protein; and 4) a mutated free cysteine (changing amino acid C292 to S292) to increase the amount of "active" or correctly folded protein.
- a human complement factor B protein analog is at least 90%, at least 95%, at least 98% or at least 99% identical to (i) SEQ ID NOs: l, 2, 3, 22 or 23; (ii) amino acids 26-764 of SEQ ID NOs: l, 2 or 3; (iii) amino acids 1-990 or 26-990 of either of SEQ ID NOs:22 or 23; amino acids 26-480 of SEQ ID NO:2; and (iv) amino acids 1 -1003 or 26- 1003 of SEQ ID NO:26.
- a human complement factor B protein analog of the invention comprises (i) SEQ ID NOs:2, 3, 22, 23 or 26; (ii) amino acids 1-480 of SEQ ID NO:2; (iii) amino acids 26-480 of SEQ ID NO:2; (iv) amino acids 26-764 of SEQ ID NOs:2 or 3; (v) amino acids 26-990 of SEQ ID NOs:22 or 23; or (vi) amino acids 26-1003 of SEQ ID NO:26.
- a complement factor B protein analog consists essentially of (i) amino acids 26-764 of SEQ ID NO:2 or 3; (ii) amino acids 26-480 of SEQ ID NO:2 or 3; (iii) amino acids 26-990 of SEQ ID NOs:22 or 23; or (iv) amino acids 26-1003 of SEQ ID NO: 26.
- Figure 1 depicts the classical and lectin complement pathways ( Figure la) and the alternative complement pathway ( Figure lb). Both pathways utilize C3b.
- the C3bBb complex is a C3 convertase which converts C3 to C3b. Spontaneous dissociation ("decay") of the C3bBb within minutes leads to its inactivation, whereas properdin stabilizes the C3bBb complex.
- C3b participates in the C3 convertase to generate additional C3b thereby creating a positive feedback loop as shown by the large arrow.
- DAF decay accelerating factor
- complement factor B analogs described herein bind C3b in place of a native complement factor B, thereby competing with native complement factor B for binding to C3b.
- Some complement factor B analogs of the invention bind C3b to create an inactive complex or a complex with significantly reduced C3 convertase activity as compared to a native C3bBb complex.
- the invention also provides complement factor B analogs comprising mutations of amino acids corresponding to those in complement factor B that interact with
- a complement factor B analog comprises mutations of amino acids that interact with DAF. These mutations include, but are not limited to, one or more mutations of amino acids corresponding to amino acids 290, 291, 323, 363, 364, or 407 of SEQ ID NO: 1. In some embodiments, these mutations are a substitution or deletion of one or more of the amino acids corresponding to amino acids 290, 291, 323, 363, 364, or 407 of SEQ ID NO: l.
- a complement factor B analog comprises one or more of the following mutations corresponding to K323E, K290A, K291A, Y363A, S364A or D407N of SEQ ID NO: 1. In some embodiments, a complement factor B analog comprises one of the following combinations of mutations corresponding to K290A/K291A, Y363A/S364A or K290A/K291A/Y363A/S364A of SEQ ID NO: l. Without wishing to be bound by theory, mutations of amino acids in a complement factor B analog that interact with
- factors/molecules that accelerate the decay of the C3bBb complex may inhibit the decay of complexes of C3b and a complement factor B analog of the invention, thereby allowing for a complement factor B analog to better inhibit complement activity.
- the invention includes nucleic acids comprising a nucleotide sequence encoding a complement factor B protein analog of the invention and includes vectors comprising these nucleic acids.
- some embodiments of the invention contemplate transducing a cell with a nucleic acid or vector encoding a complement factor B analog of the invention.
- the instant invention is not to be construed as limited to any one particular nucleic delivery method, and any available nucleic acid delivery vehicle with either an in vivo or in vitro nucleic acid delivery strategy, or the use of manipulated cells (such as the technology of Neurotech, Lincoln, RI, e.g. , see U.S. Patent Nos.
- nucleic acids of the invention encoding a complement factor B analog per se (e.g. , "naked DNA")
- Various delivery vehicles such as vectors, can be used with the present invention.
- viral vectors amphitrophic lipids, amphitrophic lipids, cationic polymers, such as polyethylenimine (PEI) and polylysine, dendrimers, such as combburst molecules and starburst molecules, nonionic lipids, anionic lipids, vesicles, liposomes and other synthetic nucleic acid means of gene delivery (e.g. , see U.S. Pat. Nos. 6,958,325 and 7,098,030; Langer, Science 249: 1527-1533 (1990); Treat et al, in "Liposomes” in "The Therapy of Infectious Disease and Cancer”; and Lopez-Berestein & Fidler (eds.), Liss, New York, pp. 317-327 and 353-365 (1989); "naked” nucleic acids and so on can be used in the practice of the instant invention.
- cationic polymers such as polyethylenimine (PEI) and polylysine
- a vector is a means by which a nucleic acid of interest (e.g. , a therapeutic nucleic acid, e.g. , that can encode a therapeutic protein) is introduced into a target cell of interest.
- a vector is typically constructed or obtained from a starting material, such as a nucleic acid capable of carrying a foreign gene or transgene and which is capable of entering into and being expressed in a target cell. Suitable starting materials from which a vector can be obtained include transposons, plasmids, viruses, PCR products, cDNAs, mRNAs and so on, as known in the art.
- Methods for obtaining or constructing a vector of interest include, but are not limited to, standard gene manipulation techniques, sequencing reactions, restriction enzymes digests, polymerase reactions, PCR, PCR SOEing, ligations, recombinase reactions (e.g., Invitrogen' s GATEWAY ® technology) other enzymes active on nucleic acids, bacteria and virus propagation materials and methods, chemicals and reagents, site directed mutagenesis protocols and so on, as known in the art, see, for example, the Maniatis et al. text, "Molecular Cloning.”
- Nucleic acids of the invention will typically comprise a promoter operatively linked to a complement factor B protein analog coding sequence.
- a promoter may be a tissue specific promoter, a cell specific promoter, an inducible promoter, a repressible promoter, a constitutive promoter, a synthetic promoter or a hybrid promoter, for example.
- promoters useful in the constructs of the invention include, but are not limited to, a phage lambda (PL) promoter; an SV40 early promoter; a herpes simplex viral (HSV) promoter; a cytomegalovirus (CMV) promoter, such as the human CMV immediate early promoter; a tetracycline-controlled trans-activator-responsive promoter (tet) system; a long terminal repeat (LTR) promoter, such as a MoMLV LTR, BIV LTR or an HIV LTR; a U3 region promoter of Moloney murine sarcoma virus; a Granzyme A promoter; a regulatory sequence(s) of the metallothionein gene; a CD34 promoter; a CD8 promoter; a thymidine kinase (TK) promoter; a B 19 parvovirus promoter; a PGK promoter; a glucocorticoid promoter; a heat shock protein
- a promoter is an MND promoter (Robbins et al., 1997, J. Virol. 71 :9466- 9474), or an MNC promoter, which is a derivative of the MND promoter in which the LTR enhancers are combined with a minimal CMV promoter (Haberman et al., J. Virol.
- a vector of the invention comprises an intron, e.g. , as part of the gene coding for a complement factor B protein analog.
- Heterologous introns are known and non- limiting examples include a human ⁇ -globin gene intron.
- An intron can be from a complement factor B gene or a heterologous intron.
- Signal sequences or leader sequences are known and can be used in complement factor B analog expression constructs. Signal sequences are translated in frame as a peptide attached to the amino-terminal end of a polypeptide of choice, the secretory signal sequence will cause the secretion of the polypeptide by interacting with the machinery of the host cell.
- this secretory signal sequence will be cleaved off.
- the human placental alkaline phosphatase secretory signal sequence is an example of a useful signal sequence.
- the present invention is not limited by specific secretory signal sequences and others are known to those skilled in the art.
- the term "signal sequence" also refers to a nucleic acid sequence encoding the secretory peptide. If a signal sequence is included, it can either be a wild type complement factor B sequence, a homologous sequence, or a heterologous sequence.
- the present invention includes viral vectors encoding a complement factor B analog(s) of the invention.
- viral vectors useful in the present invention are described in PCT Publication No. WO08/106644 and U.S. Patent Publication No.
- Viral vectors include, but are not limited to, retroviral vectors, lentiviral vectors, adenoviral vectors (see, for example, U.S. Pat. No. 7,045,344), AAV vectors (e.g., see U.S. Pat. No. 7, 105,345), Herpes viral vectors (e.g. , see U.S. Pat. Nos. 5,830,727 and 6,040, 172), hepatitis (e.g., hepatitis D) viral vectors (e.g. , see U.S. Pat. No.
- a lentiviral vector is an HIV, EIAV, SIV, FIV or BIV vector.
- the invention also provides a cell that produces a viral vector of the invention.
- BIV systems are described, for example, in Matukonis et al., 2002 Hum.
- Vector virions of the invention may be administered in vivo or in vitro to cells (e.g. , mammalian cells).
- Vectors can be used to transduce or transform cells including, but not limited to, undifferentiated cells, differentiated cells, somatic cells, primitive cells and/or stem cells.
- stem cells are intended for administration to a human and not for implantation in a suitably pseudopregnant woman for differentiation and development into an infant.
- a viral vector of the invention comprises a decay accelerating factor (DAF).
- DAF decay accelerating factor
- an enveloped viral vector includes a DAF on the viral membrane.
- a DAF is a wild-type DAF.
- a DAF is part of a fusion protein with an envelope protein, e.g., see Guibinga et al. Mol Ther. 2005 1 1(4):645-51.
- a BIV producer cell expresses a DAF.
- the complement factor B protein analogs of the invention can be produced from a cell. In some embodiments, the complement factor B protein analog is then purified from the cell and/or from cell culture medium.
- the invention includes (i) cells comprising a nucleic acid comprising a nucleotide sequence encoding a complement factor B analog of the invention and/or (ii) cells expressing a complement factor B protein analog of the invention.
- a mammalian cell is utilized.
- a prokaryotic cell is utilized.
- Host cells are typically transfected or transduced with an expression or cloning vector for protein production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, amplifying the genes encoding the desired sequences or for downstream purification and/or concentration procedures.
- Suitable host cells for cloning or expressing a coding region in a vector are prokaryote, yeast, or higher eukaryote cells.
- Suitable prokaryotes for this purpose include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B.
- eubacteria such as Gram-negative or Gram-positive organisms
- Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus
- Salmonella
- an E. coli cloning host is E. coli 294 ⁇ e.g. , ATCC 31 ,446), although other strains such as E. coli B, E. coli X1776 ⁇ e.g. , ATCC 31,537), and E. coli W3110 ⁇ e.g. , ATCC 27,325) may be suitable.
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts.
- Saccharomyces cerevisiae, or common baker's yeast is commonly used among lower eukaryotic host microorganisms.
- Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (e.g. , ATCC 12,424), K. bulgaricus (e.g. , ATCC 16,045), K. wickeramii (e.g. , ATCC 24,178), K.
- waltii e.g. , ATCC 56,500
- K. drosophilarum e.g. , ATCC 36,906
- K. thermotolerans e.g. , K. marxiamis
- yarrowia e.g. , EP402,226
- Pichia pastoris e.g. , EP183,070
- Candida
- Trichoderma reesia e.g. , EP244,234
- Neurospora crassa e.g. , Neurospora crassa
- Schwanniomyces such as
- Schwanniomyces occidentalis and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger.
- Suitable host cells can be derived from multicellular organisms.
- invertebrate cells include plant and insect cells.
- Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori have been identified and can be used for expressing proteins.
- a variety of viral strains for transfection can be used for protein expression and are publicly available, e.g., the L-l variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used according to the present invention, for example, for transfection of Spodoptera frugiperda cells.
- Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts.
- Some embodiments of the invention utilize vertebrate or mammalian cells, and propagation of vertebrate cells in culture (tissue culture) can be a routine procedure.
- Examples of useful mammalian host cell lines are a monkey kidney CVI cell line transformed by SV40 (e.g. , COS-7, ATCC CRL 1651); human embryonic kidney line (e.g. , 293 or 293T cells including either cell line subcloned for growth in suspension culture, Graham et al, J. Gen Virol. 36:59 (1977) such as 293 Freestyle (Invitrogen, Carlsbad, CA)) or 293FT; baby hamster kidney cells (e.g. , BHK, ATCC CCL 10); Chinese hamster ovary cells; Chinese hamster ovary cells/-DHFR (e.g. , CHO, Urlaub et al, Proc. Natl. Acad. Sci.
- SV40 e.g. , COS-7, ATCC CRL 1651
- human embryonic kidney line e.g. , 293 or 293T cells including either cell line subcloned for growth in suspension culture, Graham et al, J
- mouse Sertoli cells e.g. , TM4, Mather, Biol. Reprod. 23:243-251 (1980)
- monkey kidney cells e.g. , CVI ATCC CCL 70
- African green monkey kidney cells e.g. , VERO-76, ATCC CRL-1587
- human cervical carcinoma cells e.g. , HELA, ATCC CCL 2
- canine kidney cells e.g. , MOCK, ATCC CCL 34
- CF2TH cells buffalo rat liver cells (e.g. , BRL 3A, ATCC CRL 1442); human lung cells (e.g.
- a host cell may be modified to decrease or eliminate expression of an endogenous protein. For example, if a complement factor B protein analog is to be produced in a particular host cell (e.g., a CHO cell), then the host cell could be modified so as expression of the host cell's native factor B protein (e.g.
- the invention provides a method of producing a complement protein analog of the invention comprising reducing or eliminating the expression of the corresponding native complement protein in the host cell.
- Methods for reducing, eliminating or knocking out expression of a host cell protein are known in the art.
- a protein's expression level may be reduced or eliminated by engineering the host cell to express inhibitory RNA (e.g. , RNAi) specific for the RNA coding for the protein.
- Clontech (Mountain View, CA) sells various vectors and kits, such as those referred to as part of the KNOCKOUTTM RNAi Systems, for knocking down expression of proteins in a host cell.
- Other methods include gene targeting by homologous recombination which allows the introduction of specific mutations into any cloned gene, e.g. , see Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1994-1998, Sections 9.16 and 9.17. This can be used to knockout the gene expressing the host cell protein.
- a repressor domain from a transcription factor may be attached or fused to a DNA binding domain such as a zinc finger polypeptide.
- a DNA binding domain such as a zinc finger polypeptide.
- zinc finger polypeptides that bind specific DNA sequences, e.g. , see U.S. Patent Nos. 6,140,081 ; and 7,067,617; and U.S. Published Patent Applications 20060078880; 20040224385; and 20070213269.
- One skilled in the art can associate designed zinc finger polypeptides with a transcriptional repressor domain (e.g.
- a host cell would be transduced with a vector expressing the transcriptional repressor.
- This approach has an advantage over knocking out the gene of interest using homologous recombination because, in mos cases, a host cell will be diploid and it would be desirable to knock out. both gene copies.
- expression of a transcriptional repressor should repress expression of both gene copies.
- the expression of particular endogenous protein may also be reduced using compounds that will directly or indirectly reduce the expression of the particular endogenous protein.
- compounds that will directly or indirectly reduce the expression of the particular endogenous protein.
- various compounds can be used to reduce the expression of endogenous ffi expression.
- ffi protein expression has been shown to be inhibited by histamine (Falus & Meretey, Immunology 1987 60:547-551 and Falus & Meretey, Mol Immunol 1988 25(11): 1093-97), sodium butyrate (Andoh et al.
- a glucocorticoid such as dexamethasone (Dauchel et al Eur J Immunol 1990 20(8): 1669-75), platelet derived growth factor (Circolo et al 1990 The Journal of Biol Chem 265(9):5066-5071), epidermal growth factor (Circolo et al. 1990), and fibroblast growth factor (Circolo et al. 1990).
- a host cell of the invention may be cultured in the presence of any one or combination of these molecules to reduce the endogenous expression of complement factor B protein.
- a host cell expressing a complement factor B protein analog is cultured in the presence of any one or more compounds selected from the group consisting of a histamine, a sodium butyrate, a glucocorticoid (e.g. , dexamethasone), a platelet derived growth factor, an epidermal growth factor, or a fibroblast growth factor.
- a histamine e.g. , a sodium butyrate
- a glucocorticoid e.g. , dexamethasone
- a platelet derived growth factor e.g., an epidermal growth factor, or a fibroblast growth factor.
- complement factor B protein expression has been shown to be upregulated or maintained by tumor necrosis factor (TNF) (Andoh et al. Clin Exp Immuno 1999 118:23-29), estrogen (Sheng-Hsiang et al. Biology of Reproduction 2002 66:322-332), Interleukin- 1 (Dauchel et al. Eur J Immunol 1990
- a host cell of the invention may be cultured in the absence of any one or combination of these molecules to reduce the endogenous expression of complement factor B protein. Additionally, a host cell may be cultured in the presence of an inhibitor of any one or more of these compounds.
- a host cell expressing an complement factor B protein analog is cultured in the presence of any one or more compounds that inhibit a compound selected from the group consisting of a TNF, estrogen, interleukin- 1 , dexamethasone, prednisolone, cortical, and interferon-gamma.
- a compound selected from the group consisting of a TNF, estrogen, interleukin- 1 , dexamethasone, prednisolone, cortical, and interferon-gamma is reduced, e.g. , using methods as described herein.
- inhibitors of estrogen include, but are not limited to, tamoxifen.
- Inhibitors also include antibodies that bind and reduce the activity of the compound. For example, various antibodies that bind and inactivate TNF are know in the art.
- a complement factor B protein analog containing composition prepared from cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, size exclusion chromatography, affinity chromatography, immunoaffinity chromatography, tangential flow purification, diafiltration, ion exchange chromatography, hydrophobic interaction chromatography (HIC), reverse phase chromatography, heparin sepharose affinity chromatography and other known forms of separation and concentration.
- HIC hydrophobic interaction chromatography
- a mixture comprising a complement factor B protein analog and contaminants may be subjected to low pH hydrophobic interaction chromatography, e.g., using an elution buffer at a pH between about 2.5-4.5, in some cases performed at low salt concentrations (e.g., from about 0-0.25M salt) or other procedures for further purification.
- low pH hydrophobic interaction chromatography e.g., using an elution buffer at a pH between about 2.5-4.5, in some cases performed at low salt concentrations (e.g., from about 0-0.25M salt) or other procedures for further purification.
- a complement factor B protein analog of the invention is at least 90%, at least 93%, at least 95%, at least 98%, at least 99.5% or at least 99.9% pure in relation to total protein.
- the invention also provides methods of producing a complement factor B protein analog comprising expressing in a cell a complement factor B protein analog of the invention and purifying the complement factor B protein analog.
- complement factor B protein analogs of the invention There are three pathways of complement activation, the classical pathway, the alternative pathway, and the lectin pathway ( Figure 1). Described herein are examples of complement factor B protein analogs of the invention. In some embodiments, these complement factor B protein analogs can attenuate the alternative pathway of complement activation. However, based on the way all three complement pathways intersect, these analogs can diminish inflammation caused by any of the three complement pathways and thereby provide therapy for any illness whose etiology involves, at least in part, complement activation. These include, but are not limited to, early AMD, wet AMD, and geographic atrophy. Figures 1 A and IB outline complement pathways. Note that they intersect at C3b.
- the invention provides methods of treating a complement-mediated disease comprising administering to a patient a pharmaceutical preparation of the invention, a complement factor B analog of the invention or a nucleic acid or vector encoding a complement factor B analog of the invention.
- the invention also includes methods of inhibiting complement activity, wherein the method comprises administering to a human subject a mutated human complement factor B analog in an amount sufficient to inhibit a complement pathway by competing with binding of native complement factor B in the subject, wherein the mutated human complement factor B analog is an active complement factor B analog of SEQ ID NO:4 having cysteine amino acids that form disulfide bonds and a free cysteine amino acid that has been substituted by an amino acid selected from the group consisting of histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tyrosine, and valine.
- the mutated complement factor B analog comprises SEQ ID NO:2, 3, 22 or 23.
- the invention also provides methods of inhibiting complement activity, wherein the methods comprise introducing to a site of the complement activity a complement factor B analog of the invention, a nucleic acid of the invention, a viral vector of the invention, a pharmaceutical composition/preparation of the invention, or any combination thereof in an amount sufficient to inhibit the complement activity.
- a method of the invention utilizes a complement factor B is an analog of SEQ ID NO:4 having cysteine amino acids that form disulfide bonds and a free cysteine amino acid that has been substituted by another amino acid.
- the invention provides methods of inhibiting complement activity, wherein the methods comprise introducing to a site of the complement activity a mutated human complement factor B analog in an amount sufficient to inhibit the complement activity by the mutated human complement factor B analog competing with binding of native complement factor B, wherein the mutated human complement factor B analog is an active complement factor B analog of SEQ ID NO:4 having cysteine amino acids that form disulfide bonds and a free cysteine amino acid that has been substituted by an amino acid.
- this method utilizes a complement factor B analog comprising amino acids 26-764 of SEQ ID NO:2, amino acids 26-764 of SEQ ID NO:3, amino acids 26-990 of SEQ ID NO:22 or amino acids 26-990 of SEQ ID NO:23.
- Complement pathways are a part of the immune system known as the innate immune system that provides immediate protection from infection prior to activation of the humoral and cell mediated branches of the immune system. They are activated and inactivated through cascading reactions that exhibit high order kinetics but are remarkably well- regulated.
- the alternative complement pathway in particular, has evolved to cycle up with great rapidity through a positive feedback loop.
- Complement factor B protein analogs of the invention and/or the vectors that express them may advantageously be used for local and/or systemic administration to a mammal and/or to treat chronic diseases.
- a complement factor B analog inhibits a complement pathway by competing with binding of the native
- complement factor B e.g. , to C3b protein and/or factor D protein.
- This can allow attenuation of complement activity as opposed to complete blockade of the pathway. Therefore, it may be possible to downregulate complement activity to a level that is therapeutic (e.g. , alleviates some symptoms or their severity) without completely blocking complement activity.
- the present invention provides methods for treating a complement mediated disease (e.g. , a chronic disease) by local or systemic administration (e.g., i.v., intraperitoneal or oral) of a complement factor B protein analog of the invention.
- the present invention provides compositions and methods for modulating, regulating, inhibiting and/or enhancing a complement activity.
- Complement- related pathways include, but are not limited to, the classical, lectin and alternative complement pathways.
- a complement-related pathway may play a role in a particular condition, disease or diseases. Therefore, some embodiments of the invention provide methods of regulating, modifying, curing, inhibiting, preventing, ameliorating, slowing progression of and/or treating a disease state mediated by one or more complement- related pathways by administering a complement factor B analog of the invention or a nucleic acid or vector encoding a complement factor B analog of the invention.
- Such disease states or conditions include, but are not limited to, drusen formation, macular degeneration, AMD, dry eye, corneal ulcers, atherosclerosis, diabetic retinopathy, vitreoretinopathy (Grisanti ei al Invest. Ophthalmol. Vis. Sci. 32:271 1-2717), corneal inflammation, airway
- autoimmune-related diseases lupus nephritis, systemic lupus erythematosus (SLE), arthritis (e.g. , rheumatoid arthritis), rheumatologic diseases, anti-phospholipid antibody syndrome, intestinal and renal I/R injury, asthma, atypical hemolytic -uremic syndrome, Type II membranoproliferative glomerulonephritis, non-proliferative glomerulonephritis, fetal loss (e.g. , spontaneous fetal loss), glaucoma, uveitis, ocular hypertension, brain injury (e.g. , traumatic brain injury), stroke (e.g.
- a complement-mediated disease is a disease of the eye.
- a complement factor B analog or pharmaceutical composition is administered to the eye, for example, by intravitreal injection, subretinal injection, injection to the intraanterior chamber of the eye, injection or application locally to the cornea, subconjunctival injection, subtenon injection, or by eye drops.
- a pharmaceutical composition is administered to the eye, wherein the pharmaceutical composition comprises at least one complement factor B analog, e.g.
- hfB3-292S selected from the group hfB3-292S (SEQ ID NO:2), hfB3-292S-740N (SEQ ID NO:3), hfB3-292S-Fc (SEQ ID NO:22) and hfB3-292S-740N-Fc (SEQ ID NO:23).
- Age-related macular degeneration is the most common cause of decreased vision in individuals over 65 years of age in the developed world. Dry AMD is characterized by a progressive degeneration of the macula causing central field visual loss. A more acute debilitating AMD includes florid neovascularization and extravasation in the retina, known as wet AMD. There is currently no effective therapy for AMD.
- a characteristic of AMD is the accumulation of drusen, located between the basal lamina of the retinal pigment epithelium (RPE) and the inner layer of Bruch's membrane (Pauleikhoff et al, 1990 Am. J. Ophthalmol. 109, 38-43; Bressler et al, 1990 Arch.
- compositions or molecules of the invention may be delivered to drusen (e.g. , by direct injection into drusen (intradrusen injection), adjacent to drusen or intravitreal injection).
- Some embodiments of the invention can be utilized to slow the progression of macular degeneration, possibly by inhibiting drusen formation.
- Vitronectin an abundant component of drusen, is also a component of extracellular deposits associated with atherosclerosis (Niculescu et al., 1989 Atherosclerosis, 78, 197-203), amyloidosis (Dahlback et al., 1993 J. Invest. Dermatol. 100, 166- 170), elastosis (Dahlback et al., 1988 Acta Derm. Venereol. 68, 107- 1 15), and MPGN type II (Jansen et al, 1993 Am. J. Pathol. 143, 1356- 1365).
- Vitronectin is a multifunctional protein that functions in cell adhesion, maintenance of hemostasis, and inhibition of complement-induced cell lysis (Preissner, 1991 Ann. Rev. Cell Biol. 7, 275-310). Furthermore, atherosclerotic plaques share a number of other constituents with drusen, such as complement components and apoliproprotein E.
- An association between advanced AMD and atherosclerosis of carotid arteries was reported in an epidemiological study (Vingerling et al., 1995 Am. J. Epidemiol. 142, 404-409) and another study identified a significant correlation between elastotic degeneration of nonsolar-exposed dermis and choroidal neovascularization in AMD patients (Blumenkranz et al., 1986
- amyloid ⁇ peptide a major constituent of neuritic plaques in Alzheimer's disease, is also found in drusen (Johnson et al, 2002 Proc. Natl. Acad. Sci. USA, 99, 11830-11835). Amyloid ⁇ peptide has been implicated as a primary activator of complement (Bradt et al, 1998 J. Exp. Med. 188, 431-438).
- Drusen also contains multifunctional proteins such as vitronectin (Hageman et al, 1999 FASEB J. 13, 477-484) and apolipoprotein E (Anderson et al, 2001 Am. J. Ophthalmol. 131, 767-781) that play a role in immune system modulation.
- amyloid P component and 3 ⁇ 4 -antitrypsin molecules involved in the acute phase response to inflammation, such as amyloid P component and 3 ⁇ 4 -antitrypsin, have also been identified in drusen (Mullins et al, 2000 The FASEB Journal, 14, 835-846), as well as proteins involved in coagulation and fibrinolysis (factor X, thrombin, and fibrinogen) (Mullins et al, 2000 The FASEB Journal, 14, 835-846). Drusen formation and associated RPE pathology were suggested to contribute to a chronic inflammatory response that activates the complement cascade (Hageman et al, 2001 Prog. Retin, Eye Res. 20, 705-732; Johnson et al, 2001 Exp. Eye Res. 73, 887-896).
- One other form of an optic disorder arising from AMD and resulting in perturbations of the retina is geographic atrophy, which leads to death of patches of rod and cone cells, as well as of the RPE cells.
- Atherosclerosis has been shown to typically involve complement related pathways, e.g. , see Niculescu et al Immunologic Research, 3Q(l):73-80(8) (2004) and Niculescu and Horea, Immunologic Research 30(l):73-80 (2004).
- Complement activation and C5b-9 deposition typically occurs both in human and experimental atherosclerosis.
- C5b-9 may be responsible for cell lysis, and sublytic assembly of C5b-9 induces smooth muscle cell (SMC) and endothelial cell (EC) activation and proliferation.
- SMC smooth muscle cell
- EC endothelial cell
- Complement C6 deficiency has a protective effect on diet-induced atherosclerosis, suggesting that C5b-9 assembly is required for, or at least plays a significant role, in the progression of atherosclerotic lesions, e.g.
- a complement factor B protein analog of the invention is administered to a site or potential site of atherosclerosis.
- This complement factor B protein analog inhibits a pathway (e.g. , the classical and/or alternative complement pathway) which in turn inhibits the formation or activation of CSb-9 or another complement pathway related compound involved in atherosclerosis.
- a pathway e.g. , the classical and/or alternative complement pathway
- CSb-9 or another complement pathway related compound involved in atherosclerosis There may be other complement related proteins involved in
- Atherosclerosis whose formation and/or activation may be inhibited or blocked in a similar manner.
- Airway hyperresponsiveness is characteristic of various diseases including, but not limited to, asthma (e.g. , allergic asthma).
- AHR has been shown to typically involve complement related pathways, e.g. , see Taube et al , 2006 PNAS 103(21):8084-8089; Park et al, American Journal of Respiratory and Critical ("are Medicine 169:726-732, (2004);
- Some embodiments of the invention provide compositions and methods for modulating, regulating, inhibiting and/or reducing AHR in an animal, such as a human.
- Specific AHR related diseases that may be treated, alleviated, inhibited and/or ameliorated include, but are not limited to, asthma, chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis, hypersensitivity pneumonia, eosinophilic pneumonia, emphysema, bronchitis, allergic bronchitis bronchiectasis, cystic fibrosis, tuberculosis, hypersensitivity pneumonitis, occupational asthma, sarcoid, reactive airway disease syndrome, interstitial lung disease, hyper-eosinophilic syndrome, rhinitis, sinusitis, exercise- induced asthma, pollution-induced asthma, cough variant asthma, parasitic lung disease, respiratory syncytial virus (RSV) infection, parainfluenza virus (PIV) infection, rhino virus (RV) infection, Hantaan virus (e.g.
- Immune-related diseases such as autoimmune-related diseases, HLA-B27 associated inflammatory diseases, lupus nephritis and systemic lupus erythematosus (SLE) have been shown to typically involve complement related pathways, e.g. , see Thurman and Holers, J Immunology 176:1305-1310 (2006).
- Lupus nephritis is one complication of SLE. It is related to the autoimmune process of lupus, where the immune system produces antibodies (antinuclear antibody and others) against body components. Complexes of these antibodies and complement components typically accumulate in the kidneys and result in an inflammatory response.
- Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating an immune-related disease, e.g. , involving or related to a complement pathway, such as SLE.
- Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating arthritis, e.g. , rheumatoid arthritis or inflammatory arthritis.
- Paroxysmal nocturnal hemoglobinuria a potentially life-threatening disease of the blood characterized by complement-induced intravascular hemolytic anemia and thrombosis due to intravascular destruction of red blood cells (RBCs) by complement resulting in uncontrolled amplification of the complement system that leads to destruction of the RBC membrane.
- Persons with this disease typically have blood cells that are missing a gene called PIG-A. This gene allows a substance called glycosyl-phosphatidylinositol (GPI) to help certain proteins stick to cells. Without PIG-A, complement regulating proteins cannot connect to the cell surface and protect the cell from complement.
- Hereditary angioedema is a potentially life-threatening genetic condition typically caused by a deficiency of the CI inhibitor, a protein of the complement system. Symptoms include episodes of edema (swelling) in various body parts including the hands, feet, face and airway.
- Hereditary angioedema exists in three forms, all of which are caused by a genetic mutation that is inherited in an autosomal dominant form. Types I and II are caused by mutations in the SERPING1 gene, which result in either diminished levels or dysfunctional forms of the C 1 -inhibitor protein (type I HAE). Type III HAE has been linked with mutations in the F12 gene, which encodes the coagulation protein Factor XII.
- HAE HAE lead to abnormal activation of the complement system.
- Some current treatments include Ecallantide a peptide inhibitor of kallikrein (e.g. , see U.S. Patent Publication No. US20070213275), Icatibant (Firazyr, Jerini) which is a selective bradykinin receptor antagonist, and Cinryze (Viropharma, Inc.) a CI esterase inhibitor.
- Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating Paroxysmal nocturnal hemoglobinuria.
- Glaucoma is a group of diseases of the optic nerve involving loss of retinal ganglion cells in a characteristic pattern of optic neuropathy. Approximately 25% of glaucoma patients with retinal ganglion cell loss have normal ocular pressure. Ocular hypertension (OHT) is a significant risk factor for developing glaucoma and lowering it via
- Ocular hypertension and glaucoma have been shown to typically involve complement related pathways, e.g. , see Khalyfa et al , Molecular Vision, 13:293-308 (2007); Stasi et al. IOVS 47(3): 1024-1029 (2007); and Kuehn et al , Experimental Eye Research 83:620-628 (2006).
- Expression and/or the presence of C lq and C3 have been shown to be higher in retina subjected to OHT.
- Uveitis has been shown to typically be associated with the complement pathway, e.g. , see Mondino and Rao, Investigative Ophthalmology & Visual Science 24:380-384 (1983) and Jha et al. Molecular Immunology 44:3901-3908 (2007). Mondino and Rao found that mean values of all tested complement components in aqueous humor to serum measurements were increased in patients with a history of previous eye surgeries and were highest in patients with anterior uveitis. Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating uveitis.
- Diabetic retinopathy is one of the leading causes of vision loss in middle-aged individuals. Activation of the complement system is believed to play an important role in the pathogenesis of diabetic retinopathy (e.g. , see Jha et al. Molecular Immunology 44:3901- 3908 (2007)).
- Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating diabetic retinopathy.
- PV Proliferative vitreoretinopathy
- Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating PV.
- Anti-phospholipid antibody syndrome In-phospholipid antibody syndrome, intestinal and renal ischemic reperfusion VR injury, atypical hemolytic-uremic syndrome, Type II membranoproliferative
- glomerulonephritis e.g. , spontaneous fetal loss
- fetal loss e.g. , spontaneous fetal loss
- Brain injury e.g. , traumatic brain injury
- has been shown to typically involve complement related pathways e.g. , see Leinhase et al. , J Neuroinflammation 4: 13 (2007) and BMC Neurosci.7:55 (2006).
- Leinhase 2006 showed that after experimental traumatic brain injury in wild-type (fB+/+) mice, there was a time-dependent systemic complement activation. In contrast, the extent of systemic complement activation was significantly attenuated in fB-/- mice.
- Some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating neuronal cell death, traumatic neural injury (e.g. brain), complement-mediated neuroinflammation and/or neuropathology.
- Ischemia-reperfusion injury can cause increases in the production of or oxidation of various potentially harmful compounds produced by cells and tissues, which can lead to oxidative damage to or death of cells and tissues.
- renal ischemia-reperfusion injury can result in histological damage to the kidneys, including kidney tubular damage and changes characteristic of acute tubular necrosis.
- the resultant renal dysfunction permits the accumulation of nitrogenous wastes ordinarily excreted by the kidney, such as serum urea nitrogen (SUN).
- SUN serum urea nitrogen
- Ischemia-reperfusion may also cause injury to remote organs, such as the lung.
- modulators such as inhibitors, of a complement pathway (e.g., inhibitors of factor B activity), e.g.
- ischemia-reperfusion injury when administered to an animal that has, or is at risk of experiencing or developing, ischemia-reperfusion.
- these modulators prevent, reduce or inhibit at least one symptom of injury due to ischemia-reperfusion.
- Other types of ischemia-reperfusion injury that can be prevented or reduced using methods and compositions of the invention, include, but are not limited to, cardiac ischemia-reperfusion injury such as myocardial infarction or coronary bypass surgery, central nervous system ischemia-reperfusion injury, ischemia-reperfusion injury of the limbs or digits, ischemia-reperfusion of internal organs such as the lung, liver or intestine, or ischemia-reperfusion injury of any transplanted organ or tissue. See, e.g. , PCT Publication No. WO03/061765 which discusses myocardial infarction and complement pathways.
- delivery of the stem cells can be by any means, such as intracoronary injection, injection directly into myocardium (e.g. , into diseased and/or healthy myocardium (e.g. , adjacent to the injured area)).
- a mammal is treated with cytokines to mobilize their bone marrow stem cells in the circulation allowing the stem cells to traffic to the myocardial infarct.
- stem cells have been used in vivo for various applications.
- One problem with the use of stem cells in vivo is the lower than desired survival and/or seeding of the stem cells, e.g., in the area of interest.
- One significant reason for low seeding and survival of stems cells can be inflammation at the site. Therefore, the present invention provides a method of treatment and/or a method of improving stem cell survival and/or seeding.
- these methods comprise administering a composition of the invention before, during and/or after administration or mobilization of stem cells.
- complement inhibitors of the invention act as anti-inflammatory agents that will create a favorable environment for stem cells to home in and survive in the area of desired seeding (e.g., damaged heart or bone marrow) and therefore repair or replace the damaged tissue.
- Stem cells may be administered in a solution that also contains a complement factor B protein analog of the invention.
- Stem cells may be, but are not limited to, hematopoietic stem cells, embryonic stem cells, mesenchymal stem cells, neural stem cells, mammary stem cells, olfactory stem cells, pancreatic islet stem cells, totipotent stem cells, multipotent stem cells or pluripotent stem cells.
- the stem cells may be autologous, allogeneic, or syngeneic.
- some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating muscular dystrophy.
- Complement activity may contribute to corneal inflammation. Therefore, some embodiments of the invention provide methods and compositions for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating corneal inflammation, e.g. , after surgery.
- a complement factor B analog of the invention is administered via eye drops or as otherwise described herein.
- complement factor B analogs of the invention are used for regulating, modifying, curing, inhibiting, preventing, ameliorating and/or treating corneal neovascularization.
- a vector of the invention encoding a complement factor B protein analog of the invention (e.g., hfB3-292S or hfB3-292S-740N) is used to transduce cells of a blood vessel (e.g. , endothelial cells).
- a blood vessel e.g. , endothelial cells.
- cells of a blood vessel are transduced prior to implantation in an animal.
- cells of a blood vessel are transduced in vivo.
- Complement factor B analogs of the present invention can be utilized to inhibit inflammation, e.g., by inhibiting a complement activity. Therefore, complement factor B analogs can be used to reduce inflammation, e.g., in postoperative patients.
- a complement factor B analog is administered locally (e.g., perioperative delivery) to a site of surgery to inhibit inflammation, which in some cases will reduce pain and suffering.
- a complement factor B analog is administered in a solution, e.g., in a physiologic electrolyte carrier fluid.
- a complement factor B analog is delivered via perioperative delivery directly to a surgical site of an irrigation solution containing the composition.
- a desired therapeutic effect may be achieved with lower doses of agents than are necessary when employing other methods of delivery, such as intravenous, intramuscular, subcutaneous and oral.
- the solution when used perioperatively, the solution will result in a clinically significant decrease in operative site pain and/or inflammation, thereby allowing a decrease in the patient's postoperative analgesic (e.g., opiate) requirement and, where appropriate, allowing earlier patient mobilization of the operative site.
- analgesic e.g., opiate
- compositions of the invention are used (e.g., in irrigation fluid) for arthroscopy, cardiovascular and general vascular therapeutic and diagnostic procedures, uro logic procedures, general surgical wounds and wounds in general.
- Compositions of the invention may be delivered by, but not limited to, injection (e.g. , via syringe), via irrigation fluid, as part of a bandage over a wound, or in a topical application such as a solution, cream, gel or the like.
- a complement factor B analog and/or vector of the invention is administered in combination with a complement inhibiting factor, prior to, concurrently with, or after administration of the complement factor B analog and/or vector.
- a complement inhibiting factor includes, but is not limited to, a Factor H, a Factor H-like 1, an MCP, a DAF, or a soluble form of an MCP.
- a complement factor B analog or vector of the invention is administered in combination with an anti-angiogenic factor.
- Anti-angiogenic factors include, but is not limited to, endostatin, a VEGF binding molecule, PEDF, T2-TrpRS (e.g. , see U.S. Patent No. 7,273,844), sFLT (e.g. , see Kong et al. Hum Gene Ther (1998) 9:823-833), aflibercept (VEGF Trap), VEGF Trap-eye, kininostatin, ranibizumab and bevacizumab.
- a complement factor B analog and/or vector of the invention is administered in combination with LUCENTIS ® (ranibizumab), AVASTIN ® (bevacizumab), VEGF Trap-eye, aflibercept or a molecule(s) that binds VEGF and/or that inhibits angiogenesis.
- LUCENTIS ® is used to treat wet AMD. Some embodiments of the invention can also be used to treat wet AMD.
- the present invention provides methods and compositions for treating wet AMD comprising administering, separately or together, a composition of the invention in combination with LUCENTIS ® (ranibizumab), AVASTIN ® (Bevacizumab) VEGF Trap-eye, aflibercept and/or a molecule(s) that binds VEGF and/or that inhibits angiogenesis.
- LUCENTIS ® ranibizumab
- AVASTIN ® Bevacizumab
- VEGF Trap-eye e.g.
- aflibercept a molecule(s) that binds VEGF and/or that inhibits angiogenesis.
- intraocular inflammation is one of the most common adverse reactions reported after administration of LUCENTIS ® , e.g. , see the "Full Prescribing Information" for LUCENTIS ® .
- the present invention provides a method for inhibiting or reducing intraocular inflammation (e.g.
- LUCENTIS ® resulting from the administration of LUCENTIS ® comprising administering a molecule or composition of the invention prior to, at the same time, and/or after the administration of LUCENTIS ® , VEGF Trap-eye or aflibercept.
- a complement factor B analog or vector of the invention is administered in combination with another compound(s), such as a compound that inhibits T-cell activation, B-cells, TNF, interleukin- 1 (e.g. , interleukin-lb), interleukin-6 and/or interferon-gamma.
- a complement factor B analog or vector of the invention can also be administered in combination with a compound(s) that inhibits complement activity, e.g. , alternative complement activity.
- Compounds that can be used and which inhibt TNF include, but are not limited to, compounds that bind TNF, such as antibodies (e.g. , Infliximab
- REMICADE® Golimumab
- SIMPONI® Golimumab
- Adalimumab HUMIRA®
- TNF Etanercept
- Other compounds that can be used and which inhibit T-cell activation include, but are not limited to, compounds that bind B7 such as abatacept (ORENCIA®).
- compounds which downregulate B-cells can be used including, but not limited to, compounds that bind CD20 such as Rituximab (RITUXAN® and MABTHERA®).
- Complement pathways contributing to and/or causing a disease can be modulated, regulated, inhibited and/or activated using various methods and/or complement factor B protein analogs that are part of the present invention.
- compositions e.g. , pharmaceutical compositions containing a complement factor B analog of the invention, such as for therapeutic uses.
- a pharmaceutical composition comprises a complement factor B analog comprising amino acids 26-764 of SEQ ID NO:2, amino acids 26-764 of SEQ ID NO:3, amino acids 26-990 of SEQ ID NO:22 or amino acids 26-990 of SEQ ID NO:23, for example, hfB3-292S (SEQ ID NO:2), hfB3-292S-740N (SEQ ID NO:3), hfB3-292S-Fc (SEQ ID NO:22) or hfB3-292S-740N-Fc (SEQ ID NO:23).
- a pharmaceutical composition comprises a complement factor B analog consisting of amino acids 26-764 of SEQ ID NO:2, amino acids 26-764 of SEQ ID NO:3, amino acids 26-990 of SEQ ID NO:22 or amino acids 26-990 of SEQ ID NO:23.
- Examples of pharmaceutical compositions and formulations that can be used with the complement factor B analogs of the invention are described in PCT Publication No. WO08/106644 and U.S. Patent Publication No. US20100120665.
- Some embodiments of the invention include pharmaceutical preparations comprising a complement factor B protein analog of the invention, a nucleic acid of the invention, a viral vector of the invention or any combination thereof.
- Formulations are generally, but not necessarily, biocompatible solutions of the active ingredient, e.g. , comprising Hank's solution or Ringer's solution.
- Formulations for transdermal or transmucosal administration generally include, but are not limited, penetrants such as fusidic acid or bile salts in combination with detergents or surface- active agents.
- formulations can be manufactured as aerosols, suppositories, or patches.
- oral administration may not be favored for protein or peptide active ingredients; however, this type of composition may be suitably formulated, e.g., in an enteric coated form, in a depot, in a capsule and so on, so as to be protected from the digestive enzymes, so that oral administration can also be employed.
- a formulation comprises one or more of the following: citrate, NaCl (e.g. , 0.64%), potassium chloride (KC1) (e.g. , 0.075%), calcium chloride dihydrate (CaCl 2 -2H 2 0) (e.g., 0.048%), magnesium chloride hexahydrate (MgCL- 6H 2 0) (e.g. , 0.03%), sodium acetate trihydrate (CH 3 C0 2 Na- 3H 2 0) (e.g.
- a formulation comprises one or more of the following: NaCl, monobasic phosphate monohydrate, dibasic sodium phosphate heptahydrate and hydrochloric acid and/or sodium hydroxide to adjust pH and water.
- a pharmaceutical composition comprises at least one ingredient selected from the group consisting of histidine, MgCl 2 , trehalose, a polysorbate, polysorbate 20, NaCl, sucrose, arginine and proline.
- a formulation comprises one or more of the following: histidine (e.g. , about 10 mM); a, a-trehalose dehydrate (e.g., about 10% or about 50mM); MgCl 2 (e.g.
- a formulation may comprise one or more of the following: sucrose, arginine or proline.
- a formulation comprises or consists of a molecule(s) of the present invention, lOmM histidine, lOmM MgCl 2 , 50mM trehalose and 0.01% polysorbate 20.
- a formulation comprises or consists of a molecule(s) of the present invention, 1.0% NaCl and lOmM MgCl 2 .
- a formulation comprises or consists of a molecule(s) of the present invention, and a balanced salt solution enriched with bicarbonate, dextrose, and glutathione, such as BSS PLUS®.
- a formulation does not comprise trehalose.
- a formulation or composition is at a pH of about 5.5.
- a formulation or composition is at a pH of between from about 5.0 to 9.0, about 5.0 to 5.5, about 5.3 to 5.7, about 5.5 to 6.0, about 5.8 to 6.2, about 6.0 to 6.5, about 6.3 to 6.7, about 6.5 to 7.0, about 6.8 to 7.2, about 7.0 to 7.5, about 7.3 to 7.7, about 7.5 to 8.0, about 7.8 to 8.2, about 8.0 to 8.5, about 8.3 to 8.7 and about 8.5 to 9.0, whatever is suitable to retain the biological activity and stability of the active ingredient(s).
- Some formulations of the invention can be manufactured as aerosols, suppositories, eye drops or patches.
- composition for use in vivo contains a "carrier” or a
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the vector of interest is administered.
- carrier' includes, but is not limited to, either solid or liquid material, which may be inorganic or organic and of synthetic or natural origin, with which an active component(s) of the composition is mixed or formulated to facilitate administration to a subject.
- a suitable oil(s), saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are typically suitable carriers for parenteral solutions.
- solutions for parenteral are typically suitable carriers for parenteral solutions.
- parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
- Carriers can include carbohydrates such as trehalose, mannitol, glutathione, xylitol, sucrose, lactose, and sorbitol.
- Other ingredients for use in formulations may include, for example, DPPC (l,2-Didecanoyl-sn-glycero-3-phosphocholine), DOPE (1,2-Dioleoyl-sn- glycero-3-phosphoethanolamine), DSPC (l ,2-Distearoyl-sn-glycero-3-phosphocholinez 1,2- Distearoyl-sn-glycero-3-phosphocholine) and DOPC (l ,2-Dioleoyl-sn-glycero-3- phosphocholine).
- Natural or synthetic surfactants may be used. Polyethylene glycol may be used (even apart from its use in derivatizing a protein). Dextrans, such as cyclodextran, may be used. In some embodiments, cyclodextrin, tertiary amines and/or beta-cyclodextrin may be used. Bile salts and other related enhancers may be used. Cellulose and cellulose derivatives may be used. Amino acids may be used, such as use in a buffer formulation. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
- Suitable pharmaceutical excipients include, but are not limited to, starch, glucose, lactose, sucrose, gelatin, antibiotics, preservatives, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- a composition if desired, can also contain wetting and/or emulsifying agents, and/or pH buffering agents. Where necessary, a composition may also include a solubilizing agent and/or a local anesthetic such as lignocaine to ease pain at the site of the injection.
- pulmonary delivery of an agent or protein (or derivative thereof) of the present invention is delivered to the lungs of a mammal while inhaling and can mostly remain in the lungs or in some embodiments traverses across the lung epithelial lining to the blood stream, (e.g. , see Adjei et al., Pharmaceutical Research 7:565-569 (1990); Adjei et al., International Journal of Pharmaceutics 63: 135-144 (1990); Braquet et al., Journal of Cardiovascular Pharmacology 13(suppl. 5):s.
- Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers.
- nebulizers include but not limited to nebulizers, metered dose inhalers, and powder inhalers.
- Some specific examples of commercially available devices suitable for the practice of some embodiments of the invention are the ULTRA VENTTM nebulizer, manufactured by Mallinckrodt, Inc., St.
- a protein is prepared in particulate form.
- this particulate form has an average particle size of less than 10 ⁇ (or microns), most preferably 0.5 to 5 ⁇ , for delivery to the distal lung.
- Formulations suitable for use with a nebulizer will typically comprise a complement factor B analog dissolved in water, in some embodiments, at a concentration of about 0.1 to about 25 mg of biologically active protein per mL of solution.
- a formulation may also include a buffer and/or a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure).
- a nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of a protein(s) caused by atomization of the solution in forming the aerosol.
- Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing a complement factor B analog of the invention suspended in a propellant, e.g. , with the aid of a surfactant.
- a propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane,
- formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing a complement factor B analog of the invention and may also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
- a bulking agent such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
- complement factor B analogs or compositions of the invention can be administered locally or systemically.
- Useful routes of administration are described herein and known in the art. Methods of introduction or administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, intratracheal, topical, inhaled, transdermal, rectal, parenteral routes, epidural, intracranial, into the brain, intraventricular, subdural, intraarticular, intrathecal, intracardiac,
- a composition or complement factor B analog of the invention is administered to a drusen, e.g. , by injecting directly into a drusen.
- Systemic administration may be, but is not limited to, by intravenous or intra- arterial injection or by transmucosal, subcutaneous and/or transdermal delivery.
- a composition of the invention may be initially directed to a site other than a diseased site.
- a dosage level and/or mode of administration of a composition may depend on the nature of the composition, the nature of a condition(s) to be treated, and/or a history of an individual patient.
- cells expressing a complement factor B analog of the invention are
- These cells can be a cell line, xenogeneic, allogeneic or autologous.
- a complement factor B protein analog or vector of the invention is administered about once every week, month, 2 months, 3 months, 6 months, 9 months, year, 18 months, 2 years, 30 months, 3 years, 5 years, 10 years or as needed.
- a molecule or vector of the invention is administered from about every 1 to 4 weeks, about every 4 to 8 weeks, about every 1 to 4 months, about every 3 to 6 months, about every 4 to 8 months, about every 6 to 12 months, about every 9 to 15 months, about every 12 to 18 months, about every 15 to 21 months, about every 18 to 24 months, about every 1 to 2 years, about every 1.5 to 3 years, about every 2 to 4 years, about every 3 to 5 years, about every 5 to 7 years, about every 7 to 10 years or about every 10 to 20 years. It is expected that administration of a vector coding for a complement factor B protein analog would be less frequent than administration of the complement factor B protein analog.
- a pharmaceutical preparation comprises a vector encoding a complement factor B analog of the invention and the pharmaceutical preparation is administered only once to the patient.
- a vector coding for a complement factor B analog is administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times to a patient in their lifetime.
- a lentiviral vector of the invention is administered 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times to a patient in their lifetime.
- a complement factor B protein analog of the invention is administered by intravitreal injection to a human eye.
- about 15 ⁇ g to about 5 mg; about 15 ⁇ g to about 500 ⁇ g; about 100 ⁇ g to about 900 ⁇ g; about 300 ⁇ g to about 700 ⁇ g; about 500 ⁇ g to about 1 mg; about 1 mg to about 5 mg; about lmg; or about 500 ⁇ g of a complement factor B protein analog is administered by intravitreal injection to a human eye.
- a complement factor B protein analog of the invention is administered by subretinal injection or intravitreal injection of a lentiviral or adeno associated viral (AAV) vector.
- AAV adeno associated viral
- about 5xl0 6 to about 5x10 s ; about 5xl0 6 to about 5xl0 7 ; about 5xl0 7 to about 5xl0 8 ; about lxlO 7 to about lxlO 8 ; about 3xl0 7 to about 5xl0 7 ; about 2.5xl0 7 ; about 5xl0 7 ; about 7.5xl0 7 ; or about lxlO 8 transducing units of a lentiviral vector is administered by subretinal injection.
- about 5xl0 8 to about lxlO 9 ; about 5x10 s to about 7.5x10 s ; about 7.5x 10 s to about lxlO 9 ; about 6x10 s to about 9x10 s ; about 7x10 s to about 8x10 s ; about 5x10 s ; about 6x10 s ; about 7x10 s ; about 8x10 s ; about 9x10 s ; or about lxlO 9 transducing units of an AAV vector is administered by subretinal injection.
- about 5x10 s to about lxlO 10 ; about 5x10 s to about 5xl0 9 ; about 5x10 s to about 2xl0 9 ; about 2xl0 9 to about 5xl0 9 ; about 5xl0 9 to about lxlO 10 ; about 5x10 s to about lxlO 9 ; about lxlO 9 to about 3xl0 9 ; about 3xl0 9 to about 6xl0 9 ; about 6xl0 9 to about lxlO 10 ; or about lxlO 9 to about lxlO 10 transducing units of an AAV vector is administered by intravitreal injection.
- about 50 ⁇ to about 100 ⁇ , about 50 ⁇ to about 75 ⁇ , about 75 ⁇ to about 100 ⁇ , about 60 ⁇ to about 90 ⁇ , about 70 ⁇ to about 80 ⁇ , about 50 ⁇ ; about 60 ⁇ ; about 70 ⁇ ; about 80 ⁇ ; about 90 ⁇ ; or about 100 ⁇ of a complement factor B protein analog or a vector encoding a complement factor B protein analog is injected subretinally.
- about 50 ⁇ to about 1 ml, about 50 ⁇ to about 500 ⁇ , about 500 ⁇ to about 1 ml, about 250 ⁇ to about 750 ⁇ , about 250 ⁇ to about 500 ⁇ , about 500 ⁇ to about 750 ⁇ , about 400 ⁇ to about 600 ⁇ , or about 750 ⁇ to about 1 ml of a complement factor B protein analog or a vector encoding a complement factor B protein analog is injected intravitreally.
- an anti-inflammatory may be delivered in combination with a complement factor B protein analog (e.g. , hfB3-292S or hfB3-292S-740N), vector or nucleic acid of the invention.
- An anti-inflammatory may be delivered prior to, concurrently with, and/or after administration of a molecule or vector of the invention.
- an anti-inflammatory is administered in the same solution and/or same syringe as a complement factor B protein analog, nucleic acid or vector of the invention.
- a complement factor B protein analog or vector of the invention and an antiinflammatory are co-administered to the eye, e.g. , as described herein.
- anti-inflammatory drugs include, but are not limited to, dexamethasone, dexamethasone sodium metasulfobenzoate, dexamethasone sodium phosphate, fluorometholone, bromfenac, pranoprofen, RESTASISTM, cyclosporine ophthalmic emulsion, naproxen, glucocorticoids, ketorolac, ibuprofen, tolmetin, non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, diclofenac, flurbiprofen, indomethacin, and suprofen.
- Some embodiments of the invention include administration of both a complement factor B protein analog and a vector encoding it.
- a complement factor B protein analog of the invention may be delivered prior to, concurrently with, and/or after administration of a vector of the invention.
- a complement factor B protein analog of the invention is administered in the same solution and/or same syringe as a vector of the invention.
- a complement factor B protein analog of the invention and a vector of the invention are co-administered to the eye, e.g. , as described herein.
- a complement factor B analog or a nucleic acid encoding it can be delivered or administered to an animal via a cell, e.g. , as cell therapy. For example, this can be accomplished by administering or delivering a cell(s) expressing a complement factor B analog(s).
- a complement factor B analog(s) is expressed from the cell via a regulatable, inducible and/or repressible promoter.
- encapsulated cells that express a complement factor B analog(s) are delivered to an animal, e.g., see PCT Publication No. WO07078922 related to encapsulated cells.
- cells are administered locally (e.g., in a joint, intravitreal, intraretinal, intracranially etc.) or systemically (e.g. , i.v.).
- Cells to be administered to an animal can be autologous, allogeneic or xenogeneic.
- autologous cells are manipulated ex vivo to cause them to produce a complement factor B protein analog of the invention and, in some embodiments, the cells are introduced back to the animal.
- Transferring a nucleic acid comprised of a coding region to cells ex vivo can be by any method, such as, electroporation, microinjection, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, lipofection, microparticle bombardment, calcium phosphate mediated transfection, viral infection and so on.
- a selectable marker also can be introduced into the cells.
- the cells can be then placed under selection, e.g. , to enhance expression and/or to isolate those cells that express the transferred coding region (see, e.g., Loeffler & Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol.
- Recombinant cells can be delivered to a patient by various methods known in the art.
- cells can be encapsulated prior to administration, as known in the art.
- when encapsulated the cells are not autologous.
- recombinant blood cells e.g., hematopoietic stem and/or progenitor cells
- eye cells and/or pluripotential cells can be injected directly into the eye. The amount of cells needed depends on the desired effect, the animal's state, etc.
- a gene delivery system can result in transduction and/or stable integration of a gene or coding region for a complement factor B analog into a target cell.
- target cells are mammalian cells such as primate cells, and human cells.
- target cells are cells of the eye, such as retinal pigment epithelial cells, retinal cells, or pluripotential cells.
- Target cells can be in vitro, ex vivo or in vivo.
- a target cell is a stem cell.
- Stem cells include, but are not limited to, pluripotent stem cells, totipotent stem cells, hematopoietic stem cells, cancer stem cells and embryonic stem cells.
- pluripotential cells contemplated herein are not those for propagating a living entity from a zygote or blastomere.
- the instant invention also contemplates the use of a partially undifferentiated cell for implantation into the eye of a patient in need of treatment, e.g. , to regenerate cells of the eye.
- transgenic animal e.g. , nonhuman
- a transgenic animal e.g. , nonhuman
- Methods for making a transgenic animal are known in the art.
- a transgenic animal (such as a mouse) will also comprise a mutation, deletion or disruption in the Fas gene, e.g., see Macmicking et al. Cell. 81 :641-650 (1995).
- a plasmid was designed to include the coding sequence for human hfB3 with an IRES-Neo selectable marker (hfB3-IRES-Neo).
- the plasmid was synthesized by GENEART AG (Regensburg, Germany, plasmid), a fee for service contract organization.
- An Nhe I restriction site was incorporated into both the 5' and 3' ends of the coding sequence.
- the hfB3 nucleic acid coding sequence was codon optimized for optimal expression in mammalian cells.
- the gene expression plasmid, pCI (Promega, Madison, WI), was modified.
- BGH Bovine Growth Hormone
- hfB3-IRES-Neo the hfB3 coding sequence with a selectable marker
- the plasmid was sequenced in its entirety to confirm the sequence integrity of the construct (SEQ ID NO: 5).
- hfB3 protein Human wild type factor B protein and hfB3 protein have 23 cysteine amino acids (C), suggesting there is at least one unpaired free cysteine present in the protein. Disulfide bond mapping suggested the free C in biologically active hfB3 is located at the amino acid 292.
- the C at 292 is highly conserved in factor B protein among different species (Table 1, above). In this Example, this C at 292 is changed to serine (S), generating hfB3-292S.
- the hfB3 expression construct was used as the template to make the site mutation changing the C at position 292 to S using Stratagene's Site-Directed Mutagenesis Kit according to the manufacture's instructions, creating the hfB3-292S expression construct.
- Two primers were used: Forward primer 5'- CACCGGCGCCAAGAAGAGCCTGGTCAACCTGATC-3' (SEQ ID NO:6) and Reverse primer 5 '-GATCAGGTTGACCAGGCTCTTCTTGGCGCCGGTG-3' (SEQ ID NO:7).
- the underlined nucleotides indicate the mutated amino acid from C to S.
- the hfB3-292S expression cassette includes, from 5' to 3', a CMV promoter, a chimeric intron, a codon optimized coding sequence for hfB3-292S, an IRES-Neo selectable marker, and a synthetic polyA ( Figure 2).
- the entire construct was sequenced to confirm the mutation and the integrity of the construct (SEQ ID NO:8).
- the expected amino acid sequence for hfB3-292S is shown in SEQ ID NO:2.
- Stable cell lines expressing hfB3 or hfB3-292S protein were generated by transfecting 293 FreeStyle cells (Invitrogen, Cat. No. R79007) with the hfB3 or hfB3-292S expression construct.
- Transfection of plasmid DNA into the 293 FreeStyle cells was mediated by PEI (Polyethylenimine, Sigma, Cat. No. 23966)-based transfection.
- PEI Polyethylenimine, Sigma, Cat. No. 23966
- a PEI solution was prepared in sterile water at a final concentration of 1 mg/mL. The pH was adjusted to 7.0 with 5 N HC1. The solution was sterilized using a 0.22 ⁇ filter. Aliquots of the PEI were stored frozen at -80°C until use.
- the transfection protocol was as follows:
- the cells were seeded at 1 x 10 6 cells/mL in serum-free 293F Expression Medium (Invitrogen, Cat. No. 12338-018).
- PEI solution Ten microliters (10 ⁇ ) of PEI solution was diluted into 40 ⁇ of 150 mM NaCl, followed by a gentle vortex (PEI solution). The DNA and PEI solutions were incubated at room temperature for 5 minutes. The PEI solution was then added to the DNA solution and the mixture was allowed to incubate at room temperature for an additional 10 minutes and then the DNA/PEI mixture was added to the cells in the 6-well plate and the cells were incubated with agitation (200 RPM) for 5 hours at 37°C in an incubator with 8% C0 2 and 85% humidity. After 5 hours, 1.1 mL of complete 293F Expression Medium (no additives) was added to each of the wells and the incubation was continued for 72 hours.
- the cells were then harvested, washed once with the 293F Expression Medium, and placed into fresh 293F Expression Medium containing 300 ⁇ g/mL G418 (Teknova).
- 293F Expression Medium containing 300 ⁇ g/mL G418 (Teknova).
- Teknova As a negative control, an equal number of un-transfected 293F naive cells were cultured in the same G418 -containing medium.
- the cells were under G418 selection for approximately 3 weeks. By which time, the un-transfected cells in the G418 -containing medium were dead.
- the transfected cells were passed over a FICOL gradient (Sigma) to remove the dead or dying cells from the G418-resistant live population.
- the G418-resistant live population was further expanded over a period of about 2 weeks, during which the cells were spun down every 2-3 days and resuspended in fresh 293F Expression Medium containing 300 ⁇ g/mL G418.
- the G418-resistant hfB3 or hfB3-292S producing cells were seeded at a density of 2xl0 6 cells/mL in the 293F Expression Medium either in 6-well plates with 2 mL culture in each well, in 500 mL spinner flasks with 100 mL culture in each flask, or in 3,000 mL spinner flasks with 1,000 mL culture in each flask.
- the cells were incubated for 72 hours with shaking at 100 rpm on an orbital shaker in a 37°C incubator with 8% C0 2 and 80% humidity.
- the cell culture medium supernatant containing hfB3 protein or hfB3-292S protein was then harvested and centrifuged at 2,000 rpm for 10 minutes to clear cell debris after which the culture medium was filtered through a 0.22 ⁇ filter.
- Example 5 Quantitation of hfB3 and hfB3-292S Proteins
- ECL Electrochemiluminescent assay
- the assay was a sandwich immunoassay based on BioVeris's ECL Technology. Briefly, the ECL assay is formatted as a 96-well plate sandwich, one-step, and no wash assay.
- the quality control samples purified factor B from human plasma, Quidel, Cat. No.
- test samples were incubated with a master mix reagent containing a biotinylated anti-hfB monoclonal antibody (anti -human factor B monoclonal antibody, R&D Systems, Cat. No. MAB2739), a BV-TAG plus-labeled anti-hfB polyclonal antibody (anti-human factor B polyclonal antibody, R&D Systems, Cat. No. AF2739), and streptavidin-coated paramagnetic beads. The mixture was incubated for 150 minutes.
- a biotinylated anti-hfB monoclonal antibody anti -human factor B monoclonal antibody, R&D Systems, Cat. No. MAB2739
- BV-TAG plus-labeled anti-hfB polyclonal antibody anti-human factor B polyclonal antibody, R&D Systems, Cat. No. AF2739
- streptavidin-coated paramagnetic beads streptavidin-coated paramagnetic beads
- a stop solution (Borate Buffer, 250 mM, pH9.2 containing 500 mM sodium chloride and 1.6 mg/mL BSA) was added and then the plate was read on M1MR Analyzer.
- the estimated dynamic range for the assay was 9.0 to 950 ng/mL.
- Polyacrylamide electrophoresis of hfB3 protein and hfB3-292S protein under denturing but non-reducing conditions was performed by mixing samples of hfB3 protein or hfB3-292S protein with non-reducing protein sample buffer (Pierce).
- Human factor B protein purified from plasma 100 ng per sample, Quidel was used as a positive control.
- Each gel also contained a well with pre-stained protein molecular weight markers (15 (Invitrogen). The samples and the markers were heated at 95°C for 5 minutes in non-reducing protein sample buffer. The samples were loaded onto a 7.5% Tris-HCL Precast mini gel (Bio-Rad).
- the gel was run (10X SDS/Tris/Glycine Running Buffer, Bio-Rad) at 75 V for 15 minutes or until the dye front passed through the stacking gel into the resolving gel. Once the dye front entered the resolving gel, the voltage was increased to 100 V and electrophoresis contintued until the dye front ran off the gel.
- the membrane was probed with a primary antibody (monoclonal antibody against human factor B, R&D Systems, Cat. No. MAB2739) diluted to 1:10,000 in IX casein solution at room temperature for 1 hour with gentle agitation and washed in 10 mL of IX casein solution 3 times for 5 minutes each at room temperature with gentle agitation on a rocker.
- the membrane was incubated with a biotinylated goat anti-mouse IgG (secondary antibody, R&D Systems, Cat. No.
- the membranes were equilibrated in 20 mL of 0.1 M Tris pH 9.5 for 5 minutes without agitation. Excess buffer was removed from the membrane by holding the membrane vertically and touching the edge of the membrane to a Kimwipe. The target side of the membrane was placed facing up in a new container. Duolox Substrate (7 mL, Vector Laboratories) was placed directly onto the target side of the membrane which was incubated for 5 minutes in the dark. Excess Duolox was removed from the membrane by holding the membrane vertically and touching the edge of the membrane to a Kimwipe.
- the membrane was washed by submerging it in 20 mL of 0.1 M Tris pH 9.5 for 5 minutes with agitation in the dark. Excess buffer was removed from the membrane by holding the membrane vertically and touching the edge of the membrane to a Kimwipe.
- the membrane was placed in a folded plastic wrap sheet and exposed to Kodak BioMax MS X-ray film in a film cassette for 1 to 5 minutes.
- the film was placed in Kodak Developer solution (dilute 26 mL of the Developer solution into 92 mL of ddH 2 0) for 1 minute.
- the film was removed from the Developer solution and placed in Kodak Fixer solution (dilute 26 mL of the Fixer solution into 92 mL of ddH 2 0) for 1 minute. Finally, the film was rinsed with tap water and allowed to dry at room temperature.
- Human alternative complement pathway activity can be measured using a hemolytic assay as described in this Example.
- rRBCs rabbit erythrocytes
- the hemolytic activity reaction mixture was set up in V-bottom shaped 96- well plates placed on ice.
- a competition assay was set up in a total volume of 40 including 500 ng of wild type human factor B, increasing amounts of hfB3 protein or hfB3-292S protein, and GVB ++ buffer (Sigma, Cat. No. G6415).
- Fifty microliters (50 ⁇ ) of factor B depleted human serum diluted 25-fold with Mg -EGTA buffer was added to each well, followed by 10 ⁇ of Mg 2+ -EGTA washed 5 x 10 7 rRBCs. After adding the rRBCs, each sample was gently mixed in the 96 well plate using a multi- channel pipette.
- the 96-well plate was placed in a glass tray with a layer of 37°C water submerging the bottom of the plate. The tray was then placed in a 37°C water bath with orbital shaking at 110 rpm for 40 minutes. After incubation, the plate was placed on ice, 150 ⁇ of ice-cold 0.9% saline was added to each well, and each reaction gently mixed by pipetting to stop the reaction. The 96-well plate was centrifuged at 2,000 rpm in an Eppendorf 5810R centrifuge for 5 minutes (min) at 4°C without brake to pellet the rRBC at the bottom of the plate. The supernatant (180 ⁇ ) was removed from each well without disturbing the pellet and transferred to the corresponding well of a new 96-well plate. The absorbance of each sample was measured at 405 nm in a microplate reader.
- hfB3 protein and hfB3-292S protein were examined by measuring the alternative complement pathway mediated hemolysis of rRBCs.
- the assay described in Example 7 was used to test the potency of hfB3 protein or hfB3-292S protein in inhibiting the human alternative complement pathway. Each reaction was performed in triplicate.
- the raw cell culture medium from hfB3-292S protein and hfB3 protein producing cells efficiently inhibited/reduced the alternative complement pathway activity in a dose-dependent manner.
- hfB3 and hfB3-292S protein may be inhibiting alternative complement pathway activity by competing against the wild type factor B protein and/or by sequestering C3b and/or complement factor D.
- hfB3 or hfB3-292S protein were used as the starting material for purification of hfB3 protein or hfB3-292S protein.
- Soluble secreted hfB3 or hfB3-292S protein was purified from the cell culture supernatant by a combination of anion exchange (AEX), hydrophobic interaction (HIC) and size exclusion chromatography (SEC) for capturing, intermediate purification and polishing steps, respectively, using a GE A TA Purifier.
- AEX anion exchange
- HIC hydrophobic interaction
- SEC size exclusion chromatography
- the cell culture supernatant containing hfB3 protein was diluted with distilled water at 4: 1 volume ratio of culture supernatant/water to lower the conductivity to ⁇ 8 Milli Siemens per centimeter (mS/cm) and adjusted to pH 7.5 with 50 mM phosphate buffer.
- This material was loaded directly onto a pre-packed ion exchange column (POROS HQ 50, ABI) on an AKTA purifier using a P-960 pump at a flow rate of 30 mL per minute.
- the column was previously equilibrated with buffer A (50 mM phosphate buffer (PB), pH7.5, conductivity ⁇ 8 mS/cm), at a linear flow rate of 600 niL/hr ( ⁇ 1 Column Volume/min, CV/min).
- buffer A 50 mM phosphate buffer (PB), pH7.5, conductivity ⁇ 8 mS/cm
- the effluent was monitored by UV detection at 280 nm.
- buffer A and buffer B 50 mM PB and 1 M NaCl, pH 7.5
- HIC hydrophobic interaction
- the major fractions (from the AEX chromatography step) containing hfB3 protein were pooled and adjusted to contain approximately 1.4 M ammonium sulfate and 47 mM phosphate buffer, pH 7.5 (conductivity 216 mS/cm) (1.0 M ammonium sulfate and 33.7 mM phosphate buffer, pH 7.5, conductivity 169 mS/cm for hfB3-292S) by adding buffer C (1.5 M ammonium sulfate and 50 mM phosphate buffer, pH 7.5) to the sample at approximately 30: 1 volume ratio of the ammonium sulfate/phosphate buffer vs.
- the pooled sample was filtered through a 0.2 ⁇ filter and applied to a hydrophobic interaction column (HiTrap Phenyl HP, GE Healthcare) pre-equilibrated with 1.5 M ammonium sulfate and 50 mM Phosphate buffer, pH 7.5 (buffer C) (1.0 M ammonium sulfate and 33.7 mM phosphate buffer for hffl 3 -292S) at the flow rate of 300 mL/hr (1 CV/min). The retained material was eluted by decreasing the ammonium sulfate concentration in a non-linear fashion.
- the intermediate HIC chromatography step can be replaced with a two- steps HIC chromatography, e.g. , to make the purification process easier to scale-up.
- HIC chromatography HIC negative selection
- HIC column HiTrap Phenyl HP, GE Healthcare
- the flow-thru fraction from the HIC negative selection step containing hfB3 or 1B3-292S protein was then re-adjusted to contain approximately 1.5 M ammonium sulfate and 50 mM phosphate buffer, pH 7.5 (conductivity 216 mS/cm) for fB3 or 1.0 M ammonium sulfate and 33.7 mM phosphate buffer, pH 7.5, (conductivity 169 mS/cm) for hfB3-292S.
- the sample was filtered through a 0.2 ⁇ filter and applied to a hydrophobic interaction column (HiTrap Phenyl HP, GE Healthcare) pre-equilibrated with 1.5 M ammonium sulfate and 50 mM Phosphate buffer, pH 7.5 for fB3 and 1.0 M ammonium sulfate and 33.7 mM phosphate buffer for hffi 3 -292S at the flow rate of 300 mL/hr (1 CV/min).
- the retained material was eluted by decreasing the ammonium sulfate concentration in a non-linear fashion to further separate fB3 or fB3-292S protein from the remaining host cell proteins.
- the raw hfB3-292S protein cell culture medium containing a complement factor B analog with the free cysteine substituted with serine at the position 292 was subjected to RP- HPLC analysis with raw naive 293 FreeStyle cell culture medium as a negative control and raw hfB3 protein cell culture medium as a positive control ( Figure 7).
- the hfB3-292S protein cell culture medium did not produce any detectable Peak II population, whereas analysis of hfB3 protein cell culture medium showed that 35% of hfB3 was in the less active, Peak II, population.
- Figures 7A & B. Example 11. Generation and Characterization of hfB4 Expression Construct and hfB4 protein
- hfB4 protein was designed to change the aspartic acid, at amino acid 740 in hfB3, to an asparagine. This change is thought to attenuate or inhibit the function of the serine protease function of this complement factor B protein analog.
- the hfB3 expression construct (SEQ ID NO:5) described in Example 1 was used as a template to make a mutation changing the aspartic acid (D) at position 740 in SEQ ID NO:4 to asparagine (N) using Stratagene's Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA) according to the manufacture's instructions, creating the hfB4 expression construct.
- Two primers were used: Forward primer
- This hfB4 expression construct includes, from 5' to 3', a CMV promoter, a chimeric intron, a codon optimized coding sequence for hfB4, an IRES- Neo selectable marker, and a synthetic polyA. The entire construct was sequenced to confirm the mutation and the integrity of the construct.
- the expected amino acid sequence for hfB4 is shown in SEQ ID NO: 17. The only difference between the amino acid sequence of hfB3 and hfB4 is the D740N change.
- a stable cell line that expresses hfB4 protein was generated by PEI-mediated transfection and drug selection of 293 cells as described in Example 3.
- the concentration of hfB4 protein in the cell culture medium of the selected cell population was measured by ECL as described in Example 5.
- Biological activity of hfB4 protein purified as described in Example 9 using the one HIC chromatography step method, was examined by hemolytic activity assay as described in Example 7.
- Table 2 shows the inhibition of human alternative complement pathway hemolytic activity by cell culture medium containing hfB4 protein. Relative hemolytic activity was scored by hemoglobin released after hemolysis of rRBC by human alternative complement pathway activity. As shown in Table 2, hfB4 protein efficiently inhibited the alternative complement pathway activity. Table 2.
- hfB3-Fc is a fusion protein between hfB3 and an IgG Fc. Specifically, the full length of the hfB3 protein was fused with a human IgG4 Fc.
- a PCR product was amplified from the hfB3 expression construct (SEQ ID NO:5) described in Example 1 using two primers: the forward primer
- the hfB3 expression construct (SEQ ID NO:5, described in Example 1 ) was digested with EcoR I and EcoR V.
- the EcoR I/EcoR V fragment containing the N-terminus of hfB3 was ligated into phfB3Cterm-Fc which was previously digested with EcoR I and EcoR V, creating phfB3-Fc.
- the phfB3-Fc plasmid was digested with Nhe I and the fragment containing the hfB3 and Fc coding sequences was ligated into the modified pCI construct with IRES-Neo described in Example 1, creating the hfB3-Fc expression construct (SEQ ID NO: 18).
- This hfB3-Fc expression construct includes, from 5' to 3', a CMV promoter, a chimeric intron, a coding sequence for hfB3-Fc, an IRES- Neo selectable marker, and a synthetic polyA. The entire construct was sequenced to confirm the integrity of the construct (SEQ ID NO: 18).
- SEQ ID NO:21 is the amino acid sequence of the hfB3-Fc protein.
- a stable cell line that expresses hfB3-Fc protein was generated by PEI-mediated transfection and drug selection of 293 cells as described in Example 3.
- the drug selected cells were cultured at 2 x 10 6 cells/mL for 72 hours.
- hfB3-Fc protein expression was examined by subjecting 2 ⁇ of the cell culture supernatant to a non-reducing SDS-PAGE and Western blot analysis.
- two bands of hfB3-Fc protein were detected by a goat anti-factor B specific antibody (R&D Systems, Cat. No. AF2739).
- the molecular weight markers in KDa are indicated on the left.
- these two bands of hfB3-Fc protein might represent monomers and dimers of the protein.
- hfB3-Fc protein inhibited the alternative complement pathway activity.
- Example 13 Effect of Repeated Freeze/Thaw on hfB3-292S Complement Inhibition hfB3-292S protein was purified as described in Example 9 using the one HIC chromatography step method. Purified hfB3-292S protein in PBS, removed from a -80°C freezer and thawed at room temperature, was counted as the first freeze and thaw cycle.
- the hfB3-292S protein concentration was adjusted to 2 mg/mL with PBS and one aliquot of hfB3-292S was sampled and saved on ice as the first freeze-and thaw sample.
- the tube of hfB3-292S protein was then frozen by sitting the tube in a methanol/dry ice bath for 20 minutes and then thawing at room temperature till completely thawed (the second freeze and thaw cycle).
- One aliquot of the sample was sampled and set aside before repeating the next freeze and thaw cycle.
- the biological activity of samples from each cycle of freeze and thaw (total 7 times) were analyzed by measuring their ability to compete with wild type human factor B in the alternative complement pathway mediated hemolytic assay as described in Example 7.
- Each reaction contained a fixed amount of wild type human factor B (0.5 ⁇ ig) with increasing amounts of hfB3-292S.
- Table 4 represent the percentage of inhibition in the hemolytic assay.
- hfB3 and hfB3-292S proteins were purified as described in Example 9 using the one HIC chromatography step method. Purified hfB3 and hfB3-292S protein, both in PBS, were removed from -80°C. Protein concentration was re-adjusted to 2 mg/mL in PBS (pH 7.4). hfB3 and hfB3-292S proteins were equally aliquoted into three 0.6 mL eppendorf tubes (40 ⁇ per tube) and then stored at 4°C, -80°C and 37°C conditions for 7 days. The biological activity (ability to inhibit complement mediated hemolysis) of each of the stored samples was analyzed by measuring their ability to inhibit alternative complement pathway mediated hemolysis as described in Example 7.
- Protein melting temperature is a measure of the thermal stability of a protein and changes in the amino acid sequence of a protein may affect, among other things, the protein's thermal stability.
- Human factor B protein hfB contains twenty-three cysteine residues, twenty-two of which occur as disulfide bond pairs (cystine) and one of which, C292, is present in an un-paired free sulfhydrile form.
- hfB3-292S protein (the single unpaired cysteine residue of hfB3 protein was modified to serine) were compared to that of hfB protein by incubating each protein in the presence of l-anilinonapthalene-8-sulfonic acid (ANS) and measuring the increase in fluorescence of ANS at 460 nm.
- ANS l-anilinonapthalene-8-sulfonic acid
- the Tm values (average of the results from two experiments) for wild type hffi protein, hfB3 protein and hfB3-292S protein were determined to be 46.4°C, 45.1°C, and 47.0°C, respectively.
- Collagen antibody-induced arthritis is an aggressive mouse model for rheumatoid arthritis (Terato K et al, J. Immunol. (1992) 148(7):2103-8; Terato K et al, Autoimmunity (1995) 22(3): 137-47).
- a collagen antibody cocktail containing 4 monoclonal antibodies against collagen (Chondrex, Inc., Catalogue Number: 10010) with LPS boost was used to induce arthritis in six-week-old DBA/1 J male wild type mice (Jackson Laboratory).
- Group 1 had 10 mice serving as a vehicle control group where 100 iL PBS (phosphate buffered saline, pH 7.4) was injected into the tail vein on day 0, a booster injection of 25 ⁇ g LPS (List Biological Lab, Campbell, California, Catalogue Number: 421) per mouse was administrated intraperitoneal (LPS was in PBS at a concentration 500 ⁇ g/mL) on day 3, and 100 ⁇ L of PBS via the tail vein again on days 3, 5, 7, and 9.
- PBS phosphate buffered saline, pH 7.4
- Group 2 had 15 mice that were injected with the collagen antibody cocktail (0.25 mg in 100 ⁇ L PBS per mouse) via tail vein on day 0, received a booster injection of 25 ⁇ g LPS on day 3, and were administered 100 . ⁇ L PBS via the tail vein on days 3, 5, 7, and 9.
- Group 3 had 15 mice that were injected with 0.25 mg of the collagen antibody cocktail and 1 mg of hfB3-292S protein, both together in 100 iL PBS per mouse via the tail vein on day 0, administered a booster injection of 25 ⁇ g LPS on day 3, and administered 1 mg of hfB3-292S protein in 100 PBS via tail vein on days 3, 5, 7, and 9.
- mice were examined every day. Each mouse weight was recorded when joint measurement took place. Forepaws and hind limb joints were measured using calipers for both width and thickness on days -1, 4, 6, 9 and 11. The measuring sequence was left front limb, left hind limb, right hind limb and right front limb. On day 11 , all animals were sacrificed and all the limbs (left front limb, right front limb, left hind limb and right hind limb) were collected and stored in individually-labeled plastic cassettes. Each cassette was placed in a histology container box containing 10% neutral buffered formalin solution.
- each limb from each mouse was transferred to a plastic cassette separately.
- the limbs were rinsed with running water in a beaker for 30 minutes (min) at room temperature (RT) to remove fixative solution.
- each cassette was transferred to a beaker containing decalcified solution (Thermo Scientific, Catalogue number 8340) by immersion of the cassette into the solution.
- Front limbs were decalcified for 8 hours and hind limbs were decalcified for 9 hours. After 8 hours or 9 hours, the limbs were again rinsed with running water for 30 min at RT to remove decalcified solution.
- limbs were stored in 70% ethanol overnight (O/N) for the next dehydration step.
- Limbs were dehydrated by sequentially immersing into: 75% ethanol (made from 100% ethanol) for two times; 85% ethanol for two times, 95% ethanol for two times and 100% ethanol for two times, each time for 15 min at RT with shaking.
- the limbs were immersed in a 1 : 1 mixture of 100% ethanol and cedar wood oil (Fisher, Catalogue Number: 040-1) for 15 min at RT with shaking, and repeated two more times for a total of three times.
- the limbs were then immersed in 100% cedar wood oil and incubated at 40°C for 5 hrs.
- limbs were immersed in a 1 : 1 mixture of cedar wood oil and methyl salicylate (ACROS, Catalogue number 119-36-8) for 60 min at RT. The limbs were then immersed in another 1 : 1 mixture of cedar wood oil and methyl salicylate O/N at RT. Following the O/N incubation, limbs were immersed in 100% methyl salicylate for 40 min at RT, repeated one more time (a total of two times). Finally, limbs were embedded in paraffin that was prepared by incubation at 60°C for 7 hrs.
- ACROS cedar wood oil and methyl salicylate
- Paraffin sections of the mouse limbs were prepared using a microtome and cut to a 7 ⁇ thickness. The sections were incubated on a 40°C water bath and transferred to a Superfrost Plus microscope slide. The slides were dried O/N at RT, and further dried by incubation O/N on a slide warmer. The slides were kept at RT until staining.
- the slides were immersed in tap water for 5 min one time to allow the stain to develop.
- the slides were dipped quickly, 8- 12 times, into acid ethanol (200 ml 70% ethanol plus 150 concentrated HCL) to destain the sections.
- the slides were then rinsed twice for 1 min in tap water, and then once for 2 min in deionized water. The excess water was blotted from the slides prior to eosin staining.
- slides were immersed in eosin once for 20 seconds. Slides were then dehydrated by immersion into 95% ethanol 3 times for 5 min. Slides were incubated in 100% ethanol 3 times for 5 min. The excess ethanol was blotted, and the slides were incubated in xylene three times for 15 min. Covers lips were adhered to the slides using the xylene -based Permount (EMS, Catalogue number 17986-01) by placing a drop of Permount on the slide using a glass rod being careful not to form bubbles. The coverslip was then angled onto the slide and dropped gently onto the slide. The Permount was allowed to spread beneath the coverslip covering the entire section. The slides were dried O/N at RT in a chemical hood.
- EMS xylene -based Permount
- mice in Group 1 appeared to have normal joints, no detectable inflammatory cell infiltration into the joint and the cartilage and bones appeared normal (Figure 9, top panel).
- the mice in Group 2 had severe inflammation in the joints, inflammatory cell infiltration, pannus formation, cartilage damage and bone erosion ( Figure 9, middle panel).
- the mice in Group 3 treated with hfB3-292S had normal joint structure, no inflammatory cell infiltration, no cartilage or bone erosion or damage ( Figure 9, bottom panel).
- a stable cell line that expresses hfB3-292S-Fc protein (SEQ ID NO:22) was generated by PEI-mediated transfection and drug selection of 293 cells as described in Example 3.
- the drug selected cells were cultured at 2 x 10 6 cells/mL for 72 hours.
- hfB3-292S-Fc protein expression was examined by subjecting 2 ⁇ of the cell culture supernatant to a non-reducing SDS-PAGE and Western blot analysis.
- Two bands of hfB3- 292S-Fc protein were detected by a goat anti-factor B specific antibody. (Data not shown.)
- these two bands of hfB3-292S-Fc protein might represent monomers and dimers of the protein.
- hfB3-292S-Fc was purified with a Protein A column. Biological activity of purified hfB3-292S-Fc protein was examined by a hemolytic activity assay as described in Example 7. As shown in Table 6, hfB3-292S-Fc protein inhibited the alternative complement pathway activity in a dose dependent manner.
- hfB3-292SN480 is made up of the N-terminal 480 amino acids of hfB3-292S (amino acids 1-480 of SEQ ID NO:2 or amino acids 26-480 of SEQ ID NO:2 after cleavage of the secretion peptide ).
- the DNA sequence of the expression construct for hfB3-292SN480 is shown in SEQ ID NO:24 with nucleotides 1064-2509 being the coding sequence for hfB3-292SN480.
- the expression construct was transfected into 293 FreeStyle cells and selected with G418 as described previously in Example 3.
- the G418 resistant non-clonal cell culture medium was subjected to Western blot analysis for hfB3- 292SN480 expression using full-length hfB3-292S as a control (left lane).
- the Western blot analysis with a monoclonal antibody specifically for hfB3-292S detected a band approximately 55 KDa from the cell culture medium of hfB3-292SN480 cell line (right lane), suggesting that even with a 280 amino acid deletion from the C-terminus of hfB3-292S, the N-terminal 480 amino acids can be expressed at an appropriate size.
- hfB3-292S is a monomer when it is produced in mammalian cells, such as human cells as described previously, e.g., see Figure 3 described in Example 6 which shows hfB3-292S was detected as one band at approximately MW 100 KDa under non- reducing conditions, suggesting hfB3-292S is a monomer.
- Two cysteines in the hinge region of the human IgG4 Fc were mutated to ensure the fusion protein would be monomer and retain hfB3-292S's biological property for inhibiting complement activity.
- This fusion protein of hfB3-292S and the mutated IgG4 Fc was designated hfB3-292S/Fc-mono.
- the DNA sequence for this fusion protein expression construct is shown in SEQ ID NO:26.
- the corresponding amino acid sequence for hfB3 292S/Fc mono is shown in SEQ ID NO:25 with amino acids 1-764 being the hfB3-292S region and amino acids 765- 1003 being the human IgG4 Fc region with amino acids 782 and 785 being serine amino acids that were substituted for cysteine residues found in a native human IgG4 Fc.
- the hfB3-292S/Fc-mono gene expression construct (SEQ ID NO:26) was transfected into human 293 FreeStyle cells. The cells were then subjected to G418 selection. The culture medium from the drug resistant cells was subjected to Western blot analysis for the fusion protein. As shown in Figure 12, a band at approximately 115 KDa was detected by purified goat anti-human factor B antibody in this non-reducing SDS-PAGE and Western blot analysis. The two higher bands most likely were aggregates of the monomeric fusion protein.
- hfB3-292S/Fc-mono producing cells inhibited the alternative complement activity in a dose- dependent manner, suggesting that hfB3-292S's complement inhibitory activity was not lost in this monomeric hfB3-292S/Fc-mono fusion protein.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK12779642.3T DK2704744T3 (en) | 2011-05-05 | 2012-05-04 | COMPLEMENT FACTOR B-ANALOGS AND USES THEREOF |
BR112013028271-1A BR112013028271B1 (en) | 2011-05-05 | 2012-05-04 | POLIPEPTIDEO, NUCLEIC ACID, VIRAL VECTOR, PHARMACEUTICAL PREPARATION, AS WELL AS USE OF THE SAME IN THE TREATMENT OF COMPLEMENTED MEDIATED DISEASE |
AU2012250614A AU2012250614B2 (en) | 2011-05-05 | 2012-05-04 | Complement factor B analogs and their uses |
US14/115,115 US9228003B2 (en) | 2011-05-05 | 2012-05-04 | Complement factor B analogs and their uses |
CA2833931A CA2833931C (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses |
KR1020137028954A KR101949293B1 (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses |
RU2013153902A RU2639521C2 (en) | 2011-05-05 | 2012-05-04 | Analogues of complement factor b and their application |
CN201280021957.3A CN103561765B (en) | 2011-05-05 | 2012-05-04 | Complement factor B analogs and their uses |
JP2014509468A JP6162102B2 (en) | 2011-05-05 | 2012-05-04 | Complement factor B analogs and uses thereof |
EP12779642.3A EP2704744B1 (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses |
NZ616479A NZ616479B2 (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses |
SG2013081682A SG194780A1 (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses |
ES12779642T ES2738628T3 (en) | 2011-05-05 | 2012-05-04 | Complement factor B analogues and their uses |
MX2013012791A MX350445B (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses. |
ZA2013/07589A ZA201307589B (en) | 2011-05-05 | 2013-10-11 | Complement factor b analogs and their uses |
IL229243A IL229243B (en) | 2011-05-05 | 2013-11-04 | Complement factor b analogs and their uses |
US14/951,565 US9533028B2 (en) | 2011-05-05 | 2015-11-25 | Complement factor B analogs and their uses |
US15/334,339 US10415026B2 (en) | 2011-05-05 | 2016-10-26 | Complement factor B analogs and their uses |
US16/502,623 US10689637B2 (en) | 2011-05-05 | 2019-07-03 | Complement factor B analogs and their uses |
US15/931,692 US11001822B2 (en) | 2011-05-05 | 2020-05-14 | Complement factor B analogs and their uses |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161482827P | 2011-05-05 | 2011-05-05 | |
US61/482,827 | 2011-05-05 | ||
US201161497835P | 2011-06-16 | 2011-06-16 | |
US61/497,835 | 2011-06-16 | ||
US201161568518P | 2011-12-08 | 2011-12-08 | |
US61/568,518 | 2011-12-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/115,115 A-371-Of-International US9228003B2 (en) | 2011-05-05 | 2012-05-04 | Complement factor B analogs and their uses |
US14/951,565 Division US9533028B2 (en) | 2011-05-05 | 2015-11-25 | Complement factor B analogs and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012151468A1 true WO2012151468A1 (en) | 2012-11-08 |
Family
ID=47108062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/036459 WO2012151468A1 (en) | 2011-05-05 | 2012-05-04 | Complement factor b analogs and their uses |
Country Status (16)
Country | Link |
---|---|
US (5) | US9228003B2 (en) |
EP (1) | EP2704744B1 (en) |
JP (2) | JP6162102B2 (en) |
KR (1) | KR101949293B1 (en) |
CN (1) | CN103561765B (en) |
AU (1) | AU2012250614B2 (en) |
BR (1) | BR112013028271B1 (en) |
CA (1) | CA2833931C (en) |
DK (1) | DK2704744T3 (en) |
ES (1) | ES2738628T3 (en) |
IL (1) | IL229243B (en) |
MX (1) | MX350445B (en) |
RU (1) | RU2639521C2 (en) |
SG (1) | SG194780A1 (en) |
WO (1) | WO2012151468A1 (en) |
ZA (1) | ZA201307589B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
PL425133A1 (en) * | 2018-04-04 | 2019-10-07 | Gdański Uniwersytet Medyczny | Point mutants of B-factor and C2 protein, method for increasing activity of anti-tumor antibodies, pharmaceutical composition and application of mutants |
CN111893090A (en) * | 2020-08-17 | 2020-11-06 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Atherosclerosis prevention and treatment drug screening cell model and construction and application thereof |
US11274141B2 (en) | 2017-05-10 | 2022-03-15 | Wellstat Immunotherapeutics, Llc | Enveloped virus resistant to complement inactivation for the treatment of cancer |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103561765B (en) | 2011-05-05 | 2015-06-17 | 沃尔斯塔特免疫疗法公司 | Complement factor B analogs and their uses |
WO2017075170A1 (en) * | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Methods of measuring factor d activity and potency of factor d inhibitors |
AU2016370210A1 (en) * | 2015-12-16 | 2018-06-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
CN108476055B (en) * | 2015-12-31 | 2020-09-04 | 华为技术有限公司 | Beam forming method, receiver, transmitter and system |
US11345904B2 (en) * | 2016-02-24 | 2022-05-31 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
WO2008106644A2 (en) | 2007-03-01 | 2008-09-04 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
WO2010066418A1 (en) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Use of flt3 ligand for strengthening immune responses in rna immunization |
WO2010085682A2 (en) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
US20100239573A1 (en) * | 2007-08-27 | 2010-09-23 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Bb SPECIFIC ANTIBODIES |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
DE60129432T2 (en) | 2000-05-16 | 2008-04-17 | Bolder Biotechnology, Inc., Louisville | PROCESS FOR THE RECYCLING OF PROTEINS WITH FREE CYSTEIN REST |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
DK2489731T3 (en) * | 2007-07-26 | 2014-11-17 | Amgen Inc | Modified lecithin-cholesterol acyltransferase enzymes |
JP5926680B2 (en) * | 2009-07-28 | 2016-05-25 | リガセプト・エルエルシー | Broad range of ErbB ligand binding molecules and methods for preparing and using the same |
CN103561765B (en) | 2011-05-05 | 2015-06-17 | 沃尔斯塔特免疫疗法公司 | Complement factor B analogs and their uses |
-
2012
- 2012-05-04 CN CN201280021957.3A patent/CN103561765B/en active Active
- 2012-05-04 WO PCT/US2012/036459 patent/WO2012151468A1/en active Application Filing
- 2012-05-04 AU AU2012250614A patent/AU2012250614B2/en active Active
- 2012-05-04 KR KR1020137028954A patent/KR101949293B1/en active IP Right Grant
- 2012-05-04 MX MX2013012791A patent/MX350445B/en active IP Right Grant
- 2012-05-04 JP JP2014509468A patent/JP6162102B2/en active Active
- 2012-05-04 BR BR112013028271-1A patent/BR112013028271B1/en active IP Right Grant
- 2012-05-04 RU RU2013153902A patent/RU2639521C2/en active
- 2012-05-04 ES ES12779642T patent/ES2738628T3/en active Active
- 2012-05-04 SG SG2013081682A patent/SG194780A1/en unknown
- 2012-05-04 US US14/115,115 patent/US9228003B2/en active Active
- 2012-05-04 EP EP12779642.3A patent/EP2704744B1/en active Active
- 2012-05-04 DK DK12779642.3T patent/DK2704744T3/en active
- 2012-05-04 CA CA2833931A patent/CA2833931C/en active Active
-
2013
- 2013-10-11 ZA ZA2013/07589A patent/ZA201307589B/en unknown
- 2013-11-04 IL IL229243A patent/IL229243B/en active IP Right Grant
-
2015
- 2015-11-25 US US14/951,565 patent/US9533028B2/en active Active
-
2016
- 2016-10-26 US US15/334,339 patent/US10415026B2/en not_active Expired - Fee Related
-
2017
- 2017-03-30 JP JP2017067501A patent/JP2017113035A/en active Pending
-
2019
- 2019-07-03 US US16/502,623 patent/US10689637B2/en active Active
-
2020
- 2020-05-14 US US15/931,692 patent/US11001822B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
WO2008106644A2 (en) | 2007-03-01 | 2008-09-04 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
US20100120665A1 (en) | 2007-03-01 | 2010-05-13 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
US20100239573A1 (en) * | 2007-08-27 | 2010-09-23 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Bb SPECIFIC ANTIBODIES |
WO2010066418A1 (en) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Use of flt3 ligand for strengthening immune responses in rna immunization |
WO2010085682A2 (en) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
Non-Patent Citations (16)
Title |
---|
ARUMUGAM ET AL., PNAS, vol. 93, no. 12, 1996, pages 5872 - 6 |
COLOMBATTI ET AL., BLOOD, vol. 77, no. 11, 1991, pages 2305 - 15 |
GRISANTI ET AL., INVEST. OPHTHALMOL. VIS. SCI., vol. 32, pages 2711 - 2717 |
HOURCADE ET AL., J IMMUNOL., vol. 162, no. 5, 1999, pages 2906 - 11 |
HOURCADE ET AL., JBC, vol. 273, no. 40, 1998, pages 25996 - 6000 |
HOURCADE ET AL.: "Analysis of the Short Consensus Repeats of Human Complement Factor B by Site-directed Mutagenesis", J BIOL CHEM, vol. 270, no. 34, 25 August 1995 (1995-08-25), XP002484974 * |
LESAVRE P. ET AL., EUR. J. IMMUNOL., vol. 12, 1982, pages 252 - 254 |
MILDER ET AL., NAT STRUCT MOL BIOL, vol. 14, no. 3, 2007, pages 224 - 8 |
MOLE ET AL., THE J. BIOL CHEM, vol. 259, no. 6, 1984, pages 3407 - 3412 |
MUECKLER; LODISH, CELL, vol. 44, 1986, pages 629 |
PARKES ET AL., BIOCHEM J., vol. 213, 1983, pages 201 - 209 |
PERKINS; SMITH, BIOCHEM J., vol. 295, 1993, pages 109 - 14 |
See also references of EP2704744A4 |
VOLANAKIS, J.E.: "The Human Complement System in Health and Disease", 1998, MARCEL DEKKER, INC., pages: 9 - 32 |
WALTER, P., METH. ENZYMOL., vol. 96, 1983, pages 84 |
XU ET AL., J BIOL CHEM., vol. 275, no. 1, 2000, pages 378 - 85 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11248000B2 (en) | 2016-06-27 | 2022-02-15 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
EP3939591A1 (en) | 2016-06-27 | 2022-01-19 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
US10961252B2 (en) | 2016-06-27 | 2021-03-30 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
EP3532497A4 (en) * | 2016-10-26 | 2020-05-13 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
US11760810B2 (en) | 2016-10-26 | 2023-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
US11274141B2 (en) | 2017-05-10 | 2022-03-15 | Wellstat Immunotherapeutics, Llc | Enveloped virus resistant to complement inactivation for the treatment of cancer |
WO2019194689A1 (en) * | 2018-04-04 | 2019-10-10 | Gdański Uniwersytet Medyczny | Factor b and c2 protein point mutants, a method for enhancing the activity of anti- cancer antibodies, the pharmaceutical composition and the use of mutants |
PL425133A1 (en) * | 2018-04-04 | 2019-10-07 | Gdański Uniwersytet Medyczny | Point mutants of B-factor and C2 protein, method for increasing activity of anti-tumor antibodies, pharmaceutical composition and application of mutants |
US11414468B2 (en) | 2018-04-04 | 2022-08-16 | Gdanski Uniwersytet Medyczny | Factor B and C2 protein point mutants, a method for enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants |
CN111893090A (en) * | 2020-08-17 | 2020-11-06 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Atherosclerosis prevention and treatment drug screening cell model and construction and application thereof |
CN111893090B (en) * | 2020-08-17 | 2023-10-27 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Atherosclerosis prevention and treatment drug screening cell model, construction and application thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11001822B2 (en) | Complement factor B analogs and their uses | |
JP7022165B2 (en) | Factor VIII complex with XTEN and von Willebrand factor proteins, and their use | |
JP5332064B2 (en) | Treatment of diseases characterized by inflammation | |
EP2785744B1 (en) | Protein inhibitors to complement and vegf pathways and methods of use thereof | |
US20190071477A1 (en) | Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof | |
JP7275095B2 (en) | Compositions, methods and kits for treating complement-related disorders | |
KR20140064768A (en) | Anti-properdin antibodies and uses thereof | |
KR102549520B1 (en) | Fusion molecules that induce non-inflammatory phagocytosis | |
NZ616479B2 (en) | Complement factor b analogs and their uses | |
JP2022525661A (en) | Recombinant CCN domain protein and fusion protein | |
WO2023197930A1 (en) | Complement-inhibiting hybrid protein | |
WO2010102380A1 (en) | Potent vegf antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12779642 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012250614 Country of ref document: AU Date of ref document: 20120504 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2833931 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012779642 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014509468 Country of ref document: JP Kind code of ref document: A Ref document number: 20137028954 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/012791 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013153902 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013028271 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14115115 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112013028271 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013028271 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131101 |